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Aldehyde dehydrogenase (ALDH) activity is commonly used as a marker to identify cancer stem-
like cells. The three ALDH1A isoforms have all been individually implicated in cancer stem-like 
cells and in chemoresistance; however, which isoform is preferentially expressed varies between 
cell lines. We sought to explore the structural determinants of ALDH1A isoform selectivity in a 
series of small molecule inhibitors in support of research into the role of ALDH1A in cancer stem 
cells. An SAR campaign guided by a co-crystal structure of the HTS hit CM39 (7) with 
ALDH1A1 afforded first-in-class inhibitors of the ALDH1A subfamily with excellent selectivity 
over the homologous ALDH2 isoform. We also discovered the first reported modestly selective 
single isoform 1A2 and 1A3 inhibitors. Two compounds, 13g and 13h, depleted the CD133+ 
putative cancer stem cell pool, synergized with cisplatin, and achieved efficacious concentrations 
in vivo following IP administration. 13h additionally synergized with cisplatin in a patient derived 
ovarian cancer spheroid model.
Graphical Abstract
INTRODUCTION
Currently, more than half of the 21,400 U.S. women diagnosed with epithelial ovarian 
cancer (EOC) annually are expected to succumb to the disease within 5 years.1 The first line 
therapy for the majority of EOC cases is surgical debulking of the primary tumor with 
adjuvant platinum- and taxane-based chemotherapeutics to treat the residual disease.2–3 
Approximately 70% of EOC patients are initially responsive to chemotherapeutics; however, 
most relapse and ultimately become unresponsive to further chemotherapy.4
EOC tumors contain a hierarchy of heterogeneous cells consistent with the Cancer Stem Cell 
(CSC) hypothesis.5–8 New therapies which target these CSCs may improve patient outcomes 
alone or when combined with chemotherapy.9 In EOC, elevated aldehyde dehydrogenase 
(ALDH) activity is a marker of CSCs.5–7, 10–12 ALDHbright cells (the sub-population of cells 
with the greatest activity in the ALDEFLUOR assay) are more tumorigenic and 
chemoresistant than ALDHdim cells, are more prevalent in chemoresistant tumors following 
chemotherapy, and their presence within a tumor is predictive of poorer patient outcomes.
6–8, 12
There are 19 distinct genes for ALDH super-family members in humans. The primary 
function of ALDH is to oxidize endogenous aldehydes generated through various cellular 
processes to the corresponding carboxylic acids. In addition to neutralization of these 
reactive species, the 3 members of the ALDH1A subfamily also function in cellular 
signaling by generating the nuclear hormone all-trans retinoic acid (ATRA) from retinal.13 
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In some solid tumors, ATRA has been shown to activate transcription of oncogenes such as 
c-MYC, PDK-1, and cyclin D1.14 Although the strongest body of evidence supports the role 
of ALDH1A1 (1A1) in CSCs, other isoforms of the ALDH1A family are often 
simultaneously expressed.15
Given that ALDH plays a potentially critical role in CSCs, inhibition of ALDH is a potential 
strategy to target CSC and reverse resistance to chemotherapy. Indeed, knockdown or 
inhibition of 1A1 increases chemosensitivity in ovarian and other cancers.5, 16–21 ALDH1A2 
(1A2) and ALDH1A3 (1A3) have similarly been implicated in chemoresistance in other 
tumor types.22–23 Some ALDH isoforms, including 1A1, are able to divert 
cyclophosphamide metabolism, preventing generation of the active phosphoramide mustard; 
however, their ability to attenuate the effects of other chemotherapeutics such as cisplatin 
and paclitaxel is poorly understood.15
A panel of cell-permeable, single or dual isoform-selective inhibitors for 1A1, 1A2, and 1A3 
could have utility as probes for dissecting the role of the various isoforms in any number of 
applications which currently rely on siRNA knockdown. Various tumors and cancer cell 
lines differ in which ALDH1A isoforms are highly expressed. Importantly, high grade 
serous ovarian tumors, the histologic subtype responsible for 70–80% of EOC deaths, show 
strong elevation of 1A3 expression but only modest elevation in 1A1 expression. Other 
histologic subtypes show significant elevation of both isoforms.24–25 The inability of 
existing 1A1 selective inhibitors to inhibit ALDEFLUOR in 1A3 high cell lines has 
previously been demonstrated.26
There are a number of small molecule ALDH inhibitors reported in the literature (Figure 1).
13, 15
 Many bear an electrophilic warhead and rely on reversible or irreversible covalent 
interaction with the ALDH catalytic cysteine to achieve potency. Design of highly isoform 
selective compounds employing these warheads is complicated by the presence of this 
critical cysteine throughout the ALDH family. One of most widely studied ALDH inhibitors, 
DEAB (1), inhibits at least 6 isoforms of ALDH with an IC50 <15 μM and is a substrate of at 
least 5 isoforms, including 1A1.27 Compound 1 requires concentrations of ~100 μM to 
induce chemosensitization of CSCs.28 Disulfiram (2), a non-selective covalent ALDH 
inhibitor approved for treatment of alcoholism, is rapidly metabolized into several covalent 
ALDH inhibitors with variable isoform selectivity.13 While 2 is also reported to deplete 
CSCs in combination with chemotherapy, this effect likely does not result from its action on 
ALDH.29–31 Win 18,446 (3) is a potent inhibitor of the ALDH1A subfamily (1A1, 1A2, 
1A3 Ki = 285, 56, and 261 nM respectively).32 Unfortunately, 3 also inhibits ALDH2 and is 
a known teratogen due to its ability to chelate zinc, making it an imperfect tool for the study 
of ALDH1A biology.33 Hurley and colleagues disclosed the non-covalent 1A1 inhibitor high 
throughput screening (HTS) hits 4 and 5a along with co-crystal structures.34–35 Soon 
thereafter, compound 5b was disclosed elsewhere.36 Recently, a scaffold-hopping approach 
to improve the cell permeability of 5b yielded compound 6 and other similar analogs. 
Compound 6 exhibits potent and highly selective 1A1 inhibition (1A1 IC50 = 7 nM; 1A2, 
1A3, ALDH2, ALDH3A1 IC50s > 1μM ) and potent inhibition of ALDEFLUOR in MIA 
PaCa-2 cells, which preferentially express 1A1. Furthermore, this series was able to 
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sensitize a paclitaxel resistant ovarian cancer cell line to treatment with paclitaxel.37 To our 
knowledge there are no selective inhibitors of 1A2 or 1A3.13, 15
The high throughput screen which identified 4 and 5a also yielded the pyrazolopyrimidinone 
CM39 (7). This compound was an attractive lead for the development of ALDH1A 
subfamily inhibitors because it exhibited reasonably ligand-efficient inhibition of 1A1 (IC50 
= 0.9 μM, LE = 0.32) and good selectivity (<20% inhibition of ALDH2 and 3A1 at 20uM).
34
 A further screen of selectivity showed ~50% inhibition of 1A2 and 1A3 at 20 μM and 
little activity against other ALDH isoforms (vide infra). Following our successful acquisition 
of an x-ray crystal structure of 7 bound in the 1A1 active site (vide infra), we undertook the 
rational design and synthesis of analogs. Herein we report the ability of these analogs to 
inhibit ALDH1A with widely varying selectivity profiles. We also examine the ability of 
selected compounds to inhibit cellular ALDH function using ALDEFLUOR, to deplete the 
CD133+ putative cancer stem cell pool, and to synergize with cisplatin in two ovarian cancer 
cell lines and in patient derived ovarian cancer spheroids. Aqueous solubility and metabolic 
stability were assessed for select compounds to guide future optimization of in vivo probes.
RESULTS and DISCUSSION
Chemistry
As shown in Scheme 1, synthesis of compounds 7, 11, 12a-d,f-h, and 13a-h began with the 
commercially available pyrazole 8a.38 Treatment of 8a with the appropriate aryl 
isothiocyanate in refluxing toluene afforded the thioureas 9a and 9b which precipitated from 
the reaction mixture upon cooling. Ring closure to generate thiopyrimidinones 10a and 10b 
proceeded in aqueous NaOH at reflux. Selective S-alkylation with 3-fluorobenzyl bromide 
yielded compounds 7 and 11. Subsequent N-alkylation resulted in a mixture of regioisomers 
12a-d,f-h and 13a-h which were easily separated by flash chromatography on silica. 
Regioisomeric assignment was made by NOE; in all cases the 1-alkyl-pyrazoles 12 eluted 
before the corresponding 2-alkyl-pyrazoles 13.
In a departure from our earlier synthetic strategy, we envisioned an alternative route to 12e 
and 15a-m that would use readily available amines rather than the corresponding 
isothiocyanates to introduce diverse R3 substituents as shown in Scheme 2. The synthesis of 
14 has been previously accomplished by treating commercially available pyrazole 8b with 
thiophosgene under Schotten-Baumann conditions; however, we found the low yield, 
difficult purification, and use of noxious reagents to be unsatisfactory.39 After screening 
many reported isothiocyanate-forming conditions employing carbon disulfide as the 
thiocarbonyl source, we found that treatment of 8b with NaH and CS2 followed by the slow 
addition of I2 afforded 14 in good yield following a simple purification.40 Isothiocyanate 14 
reacted with amines rapidly under mild conditions to form thioureas. Subsequent addition of 
NaH in the same pot facilitated cyclization to the thiopyrimidinone. For the majority of 
arylamines, adding 3-fluorobenzyl bromide at this point completed the transformation of 14 
to 12e, 15a-i in one pot. For alkylamines and 2-aminopyridine (15j-l), an aqueous workup 
prior to S-alkylation with 3-fluorobenzyl bromide reduced the formation of several 
unidentified side products. The thiourea resulting from treatment of 14 with 8N ethanolic 
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methylamine spontaneously cyclized to form the thiopyrimidinone. Following removal of 
volatiles, S-alkylation of this intermediate with 3-fluorobenzyl bromide under basic 
conditions afforded 15m.
Characterization of lead 7
To establish a benchmark and guide design of new analogs, we further characterized 
compound 7. As shown in Figure 2A, 7 has excellent selectivity for 1A1 vs. 2, 1B1, 3A1, 
4A1, Page 8 of 61 5A1, and 1L1 yet modestly inhibits 1A2, 1A3. Despite the presence of a 
potentially electrophilic isothiourea, 7-mediated inhibition of 1A1 was fully reversed 
following gel filtration, indicating it is non-covalent (Supplemental Figure S1). Similar to 
other non-covalent inhibitors of 1A1, 7 was found to be non-competitive with respect to the 
substrate acetaldehyde with a Ki = 0.38 ± 0.05 μM and uncompetitive with respect to NAD+.
35
 Liabilities of the lead with regard to its potential as a therapeutic included a half-life of 9 
minutes in the presence of MLMs and poor aqueous solubility (2 μM), both of which could 
be attributed to high lipophilicity (cLogP of 5.2).41 As shown in Figure 2B, compound 7 was 
inferior to the widely-used ALDEFLUOR control compound DEAB (1) at reducing 
ALDHBright PEO1 cells at concentrations up to 30 μM. This result suggested that 
ALDH1A1 selective inhibition is not sufficient to inhibit ALDEFLUOR in this 1A3 high 
cell line. It is important to note that while DEAB is a 57nM 1A1 selective inhibitor, it only 
inhibits ALDEFLUOR above its 1A3 IC50 (3 μM).27 More potent ALDEFLUOR inhibition 
for DEAB in two 1A1 high cell lines, MIA PaCa-2 (IC50 3.4 μM) and HT-29 (IC50 1.7 μM), 
has previously been reported.26
Crystal structure of ALDH1A1 complexed with 7
To guide the design of new analogs, an X-ray crystal structure of 7 bound to N121S 
ALDH1A1 was obtained with a resolution of 2.1Å (PDB code 5TEI, Figure 3A, Table S1, 
Figure S2). The known single nucleotide polymorphism (NCBI rs1049981) resulting in the 
N121S missense mutation has been found in a small percentage of the HapMap-CEU 
population. There is no known clinical significance to the mutation and its structure is highly 
similar to the wild-type.34–35 The N121S enzyme crystallizes under identical conditions to 
the WT enzyme, but complexes with inhibitors are frequently easier to obtain, presumably 
due to dynamic fluctuations within the active site that are not detectable by crystallography 
and have little impact on observed potency. Furthermore, the IC50 of 7 was comparable for 
the WT and N121S (0.9 and 0.7 μM respectively, Table 1, Supplementary Figure S1) Similar 
to the complex with 5a (PDB code 4WP7), the bicyclic ring binds across the exterior 1/3 of 
the substrate binding pocket. The 3-fluorobenzyl group extends in towards the catalytic 
nucleophile (C303) and makes aromatic contacts with F171, W178 and F466. This binding 
mode is orthogonal to that for 4 (PDB code 4X4L), in which its tricyclic ring system extends 
toward both C303 and W178 (Figure 3B).35 The core heterocycle of 7 binds similarly to the 
substituted xanthine ring of 5a, binding beneath Y297 and occupying the additional active 
site volume afforded by the 1A1-specific residue, G458. Other ALDH½ isoenzymes have 
either an Asn or Asp residue at position 458 which may drive selectivity by prohibiting a 
similar binding mode in these isoforms. There appears to be room for small substitutions on 
the pyrazole at N-1 but not N-2, suggesting that larger substituents at these positions will not 
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be tolerated without alteration of the binding pose. The lipophilic 2-methylphenyl ring binds 
near a relatively polar region of the 1A1 active site, suggesting that appropriate polar 
substituents could improve or maintain binding affinity while lowering cLogP. The 3-
fluorobenzyl ring attached to the sulfur projects into the deepest section of the active site and 
maximizes contacts with the aromatic residues near the catalytic nucleophile, C303. The 
apparent goodness of fit of the 3-fluorobenzyl substituent, as well as its expected metabolic 
stability, encouraged us to retain it for the initial set of analogs based on 7.
Structure-Activity Relationships (SAR)
All new compounds were tested for inhibition of ALDH1A1, 1A2, 1A3, and 2. Selected 
compounds were also tested for thermodynamic aqueous solubility and stability in the 
presence of mouse liver microsomes (MLM).
We began our SAR campaign by generating N-alkylated analogs to fill the small lipophilic 
pocket adjacent to Ile304. We also hypothesized that eliminating the moderately acidic (pKa 
= 8.142) pyrazole N-H might improve cell permeability. Encouragingly, methylation at N-1 
(Table 1, 12a) resulted in a modest improvement in 1A1 inhibition compared to 7. 
Consistent with a reduction in cLogP42 aqueous solubility was also improved. Installing the 
larger cyclopropyl-methyl substituent (12b) improved the 1A1 IC50 but did not improve 
potency against 1A2 or 1A3. The unfavorable cLogP (5.6) of 12b encouraged us to explore 
less lipophilic oxetanyl analogs 12c-d. 12c maintained comparable potency against 1A1 with 
substantially lower cLogP (4.7). The homologated oxetane 12d was 2-fold less potent 
against 1A1, suggesting that larger substituents would not be tolerated.
In an effort to pare down the CM39 scaffold to the key pharmacophore, we discovered that 
removing the R2 methyl markedly improved inhibition of 1A2 and 1A3 affording compound 
11, which potently inhibited all three ALDH1A isoforms but retained excellent selectivity 
over ALDH2. We revisited the panel of N-1 substituents (12e-h) and observed different SAR 
trends. The small N-methyl substituent of 12e afforded the most potent of the four analogs 
tested but exhibited very poor solubility. Given the lower cLogP of 12e compared to 7 or 
12a, we believe the poor solubility is best explained by the increased planarity of 12e. The 
MLM stability of 12e was unchanged relative to 7. The bulkier cyclopropyl-methyl and 
oxetanyl-methyl substituents of 12f and 12h both resulted in 4-fold or greater reduction in 
potency against the ALDH1A family relative to 12e. The smaller oxetanyl substituent of 12g 
was only slightly less potent than 12e and afforded a modest improvement in aqueous 
solubility. The divergent SAR trends for 12a-d compared to 12e-h suggested that, upon 
removal of the o-methyl, a new binding mode was accessible.
N-2 alkylated analogs were also tested to further probe the flexibility of the binding mode 
depicted in the CM39 crystal structure (Table 2). 13a exhibited a similar ALDH1A 
inhibition profile to 12a. Extending to bulkier substituents (13b-d) resulted in improved 1A1 
potency with the cyclopropyl-methyl being optimal, providing strong evidence for an 
alternative binding mode. 13a-d were more potent against 1A3 than the corresponding N-1 
regioisomers (12a-d), as exemplified by the modestly 1A1/1A3 selective cyclopropyl-methyl 
analog 13b. As we observed previously, removal of the o-methyl significantly improved the 
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inhibition of 1A2 and 1A3 in analogs 13e-h. Oxetane was the optimal N-2 substituent to 
achieve inhibition of all three ALDH1A isoforms (13g), while cyclopropyl-methyl (13f) 
afforded a potent 1A1/1A3 inhibitor with >5-fold selectivity over 1A2. Despite having 
higher values for cLogP than the corresponding N-1 regioisomers, N-2 analogs were 
observed to be more polar by normal and reverse phase chromatography. Consistent with 
this observation, the solubility of N-2 methyl analog 13e was substantially improved over 
regioisomer 12e. 13e was also moderately more stable in the presence of MLMs, leading us 
to prioritize N-2 substituted analogs for further pharmacokinetic studies. Curiously, 
appending the oxetanyl substituent at N-2 (13g) was not favorable for solubility as was 
observed at N-1 (12g). Reasonable aqueous solubility was restored for the homologated 
analog 13h. Perhaps resulting from steric blocking of N-dealkylation, 13g and 13h were 
about 2-fold more stable in the MLM assay than 13e. Exquisite selectivity over the closely 
related ALDH2 isoform was maintained for all tested analogs, positioning the series as a 
useful set of tool compounds to probe the biological effect of ALDH1A inhibition.
The substantial increase in inhibition across the ALDH1A subfamily upon removal of the o-
methyl in R3 (12e) prompted us to further probe the effect of varied substitutions at this 
position as shown in Table 3. We retained the N-1 methyl substituent of 12e for synthetic 
ease. Although we had evidence to suggest the binding mode of 7 depicted in the crystal 
structure was flexible, we began by designing R3 analogs according to the crystal structure. 
The R3 region of 7 is flanked by a region of exposed peptide backbone (residues 458–460) 
and the sidechain of N121 (S121 in WT), suggesting that polar interactions in this region 
might improve binding over the lipophilic 2-methylphenyl. Additionally, as the R3 methyl-
phenyl is partially solvent exposed, polar solubilizing moieties were expected to improve 
pharmacokinetic properties without substantial loss of potency. Unfortunately, all attempts to 
alter the phenyl present in 12e resulted in significant loss of activity across the ALDH1A 
subfamily. Nevertheless, interesting selectivity trends did emerge. Substituents other than 
methyl at the ortho position (Cl, OMe) also rendered compounds 1A1 selective, but 
decreased 1A1 potency (15a and 15e) relative to proteo analog 12e. Chloro analog 15a 
showed a twofold improvement in potency (1A1 IC50 = 250 nM) compared to 12a. Because 
of the comparable size of Cl and CH3, this difference suggested a preference for electron 
withdrawing groups; however, the electron-deficient fluorinated analog 15d was merely 
equipotent with 12e despite the similar size of the substituents. Electron-rich methoxy 
analog 15e was four-fold less potent against 1A1 than 15a. Meta substituents rendered 
analogs 15b and 15f modestly 1A2 selective. Consistent with our hypothesis that disruption 
of planarity is favorable for solubility in this series, 15b was considerably more soluble than 
12e. Addition of a chlorine in the para position resulted in a 1A2/1A3-selective inhibitor vs 
1A1 (15c), while para methoxy analog 15g exhibited very modest selectivity for 1A3. 
Pyridyl analogs 15h-j were substantially less potent across the ALDH1A family, perhaps 
reflecting a desolvation penalty without formation of productive hydrogen bonds within the 
active site. Benzyl analog 15k inhibited 1A1 and 1A2 with good selectivity over 1A3. 
Homologation to phenylethyl analog 15l resulted in potent inhibition of 1A3 (IC50 = 180 
nM) with more than 5-fold selectivity over 1A1 and 1A2 and greater selectivity over other 
ALDH isoforms as shown in Figure 4. Replacing the phenyl of 12e with a methyl group led 
to a large decrease in potency (15m). The steep SAR at R3, inconsistent with partial solvent 
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exposure, was further evidence that the binding mode depicted in the crystal structure of 7 
was no longer relevant.
Crystal structure of ALDH1A1 complexed with compound 13g
To elucidate the change in binding mode we suspected, we obtained a co-crystal structure of 
N121S ALDH1A1 with compound 13g resolved to 2.0Å (PDB code 6DUM) (Figure 5, 
Table S1, Figure S3). The structure revealed a dramatically different binding pose for 13g in 
which the R3 N-phenyl is situated near the catalytic cysteine. The N-phenyl is flanked by 
Phe171 and Phe466, potentially explaining why steric bulk and polarity are not tolerated at 
the ortho and meta positions (Table 3). It is more difficult to justify why para substituents are 
so poorly tolerated. In contrast to the binding pose of compound 7, there is room for fairly 
large N-2 pyrazole substituents to extend across the mouth of the active site. Consistent with 
this observation, larger substituents at N-2 improve 1A1 potency (13f and 13g) relative to 
methyl analog 13e. As expected, given that large substituents at N-1 would project into 
solvent, compounds 12f-h do not improve potency over methyl analog 12e.
Homology Modeling
In order to better understand the SAR of these compounds, we performed a molecular 
docking study of select compounds against all isoforms of the ALDH1A class. At the time 
this manuscript was drafted, no high quality crystal structures were available for 1A2 and 
1A3. Recently, Chen et al. disclosed high quality structures of 1A2 with small molecules 
bound in the active site (e.g. PDB code 6B5H).43 We opted for building our own homology 
models of 1A2 and 1A3 isoforms based on the PDB structure of ALDH1A1 reported here. 
Homology models were developed on Swiss-Model Workspace using ProMod3. The quality 
of the models was assessed by QMEAN scores as well as Ramachandran plots 
(Supplementary Figure S4,5). Furthermore, when comparing all residues in our 1A2 
homology model with PDB:6B5H, the average RMSD was 0.76Å, indicative of an excellent 
homology model (Supplementary Figure S4). In order to prove robustness of our docking 
methods, we docked co-crystal ligands 7 and 13g into the binding site of ALDH1A1. The 
docked poses for both ligands were in good agreement with the crystal structures with 
RMSD values of 0.8 and 1.0 Å for 7 and 13g, respectively (Supplementary Figure S6).
The molecular docking study of compound 7 in ALDH1A2 (Figure 6B) and1A3 (Figure 6C) 
shows that the 2-methyl substituent on the phenyl ring would clash with non-conserved 
residues Leu477 (1A2) or Leu471 (1A3) if it adopted the same binding pose as in 1A1. The 
corresponding residue Val460 in ALDH1A1 (Figure 6A) avoids this steric clash with 2-
methyl substituent. These observations agree with the observed 1A1 selectivity of 7.
Des-methyl compound 11, which is active against all ALDH1A isoforms, docks well into 
the active site of all three ALDH1A proteins (Figure 7). For ALDH1A1, the 3-fluorobenzyl 
ring engages in pi-pi interactions with both Phe171 and Trp178. The bicyclic ring makes a 
pi-pi interaction with Tyr297 and van der Waals interactions with Gly458 and Tyr297, while 
the phenyl ring participates in van der Waals interactions with Val460 and Asn121. In the 
active site of ALDH1A2, the bicyclic ring forms pi-pi interaction with Phe314 and a van der 
Waals interaction with Asn475. The 3-fluorobenzyl ring makes a pi-pi interaction with 
Huddle et al. Page 8
J Med Chem. Author manuscript; available in PMC 2019 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Phe188 and van der Waals hydrophobic interactions with Trp195, while the phenyl ring 
engages in van der Waals hydrophobic interactions with Val138 and Leu477. In the case of 
ALDH1A3, the bicyclic ring of compound 11 makes a pi-pi interaction with Phe308 and a 
van der Waals interaction with Asn469. The 3-fluorobenzyl ring forms a pi-pi interaction 
with Phe182 and a van der Waals hydrophobic interaction with Trp189, while the phenyl 
ring makes van der Waals hydrophobic interactions with Ile132, Phe182 and Leu477.
When inhibitor 12g was docked, it adopted a similar pose to the crystal structure of the 
regioisomer 13g. The similar potency and isoform selectivity for these compounds is 
consistent with the relatively solvent exposed nature of the oxetane in both cases. The phenyl 
ring docks deep in the cavity and forms pi-pi interactions with Phe171 and Trp178 (1A1), 
Phe188(1A2), Phe182(1A3) and van der Waals interactions with Trp195(1A2), Trp189(1A3) 
as shown in Figure 8. The 3-fluorobenzyl ring makes van der Waals interactions with Val460 
and Asn121 (1A1), Leu477 and Val138 (1A2), and Leu471 and Ile132(1A3). The bicyclic 
ring of 12g engages the same residues as 11 for the three isoforms. The predicted binding 
mode of Compound 13h (Supplementary Figure S7), which is also active against all three 
isoforms, is similar to that of 12g.
The modestly ALDH1A3 selective compound 15g, which has a methoxy group at the 4-
position of the phenyl ring, is predicted to bind ALDH1A3 in a similar fashion to 7 (Figure 
9). The positioning of the methoxy group near the ALDH1A3 specific residue Glu135, may 
explain the selectivity of 7 towards ALDH1A3. In contrast, ALDH1A1 bears Ala124 at this 
position which could not form a favorable polar contact with the methoxy.
Confirming activity in live cells
We next performed the ALDEFLUOR assay (Stem Cell Technologies) in PEO1 and 
OVCAR5 cells, to confirm ALDH inhibition in live cells (Figure 10A, B). Given the 
association between ALDH1A3 expression and the high grade serous histology we chose 
cell lines with high 1A3 activity (Supplementary Figure S8).24 PEO-1 is classified as a high 
grade serous ovarian cancer cell line.44 OVCAR5, a commonly used cell line originally 
classified as high grade serous ovarian, may be gastrointestinal in origin.45 The ALDH1A 
subfamily inhibitors 12g, 13g, and 13h all exhibited strong inhibition of ALDEFLUOR 
signal with significant activity in both cell lines at 1 μM and reductions of greater than 50% 
at 10 μM. While both compounds inhibited ALDEFLUOR to some extent, the 1A3 selective 
compound 15l was significantly better than 1A1 selective DEAB. The 1A2 selective 
inhibitor 15b showed little to no inhibition at 30 μM. Compound 15b is reasonably soluble 
and has a lower TPSA and molecular weight than the efficacious inhibitors, suggesting that 
this effect is indeed due to its isoform selectivity profile and not simply an inability to enter 
the cell. Despite having biochemical 1A3 IC50s (0.12–0.17 μM) that are very similar to 15l 
(0.18 μM), the inhibitors of all 3 ALDH1A isoforms, 12g, 13g, and 13h, were somewhat 
superior in the ALDEFLUOR assay (statistically significant differences at 3 μM are 
highlighted in Figures 10A and 10B). Although we cannot rule out variable cell penetration 
for the compounds as a potential cause, this may indicate that low levels of 1A1 and/or 1A2 
expression in these cell lines slightly diminish the effective ALDEFLUOR inhibition of 
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1A3-selective 15l. Low levels of 1A1 and 1A2 mRNA were in fact detected in OVCAR5 but 
not PEO1 cells (Supplementary Figure S8).
In addition to ALDH, the surface glycoprotein CD133 has also been used as a marker of 
stemness in many cancers including ovarian cancer, and its expression is correlated with 
poorer patient outcomes in ovarian cancer.7, 46 Interestingly, treating PEO1 and OVCAR5 
cells with inhibitors 12g, 13g, and 13h also elicited a dose dependent preferential reduction 
in the percentage of CD133+ cells (Figure 10C, D). The 1A1 selective DEAB was not 
effective in this assay, and the ALDH1A2 selective 15b had only a modest dose-independent 
effect. The 1A3 selective compound 15l depleted CD133+ cells at 30 μM, but had no effect 
at 10 μM.
Evaluation of synergy with Cisplatin
ALDH1A family members are known to play a role in resistance to multiple chemotherapy 
agents 47–50 and a reduction in their activity has been shown to restore sensitivity.16–22, 51–53 
Therefore, we investigated the ability of our inhibitors with the best ALDEFLUOR activity 
to increase sensitivity to and potentially synergize with cisplatin in PEO1 and OVCAR5 
cells. Using the Chou-Talalay method, we determined that 12g, 13g, and 13h are highly 
synergistic (Combination Index values <1 indicate synergy with smaller numbers indicating 
stronger synergy) with cisplatin (Fig. 11A, B, Supplemental Fig. S9).54 The observed 
synergy for 12g and 13g at 1 μM was already strong but it was improved by increasing the 
concentration of these compounds to 10 μM. While 12g and 13g alone did not show 
cytotoxicity at these doses, 13h did and, therefore, had to be tested at lower doses. 
Nonetheless, synergy with 13h was observed at concentrations as low as 0.3 μM. As a 
control, we included the ALDEFLUOR inactive 15b, which was somewhat synergistic but 
was overall the least effective compound, especially at the lower concentrations of cisplatin.
We similarly evaluated synergy using primary patient derived samples in a 3-D tumor 
spheroid assay; a platform which mimics in vivo growth (Fig 11C).55–56 As 13h showed 
comparable synergy to 12g and 13g at 3-fold lower concentrations in the initial synergy 
studies, we tested this compound. Ovarian cancer spheroids, compared to 2D monolayer 
culture, are more resistant to standard therapies and express higher levels of 
ALDH1A1.20, 57 The sphereoids employed in this experiment express both 1A1 and 1A3 as 
determined by qRT-PCR (Supplementary Figure S10). Treatment of patient derived ovarian 
cancer spheroids with 0.3 μM 13h did not significantly reduce viability as monotherapy. 
However it was highly synergistic with all three concentrations of cisplatin tested (Fig 11C, 
Combination indices 0.08–0.27).54 Similar to our observations, Condello et al. report that 
concentrations of 4 below its ALDEFLUOR IC50 are able to potentiate the effects of 
cisplatin against ovarian cancer spheroids.20
In Vivo Murine Metabolic Stability
Given that 13g and 13h showed promising cellular activity and were the most stable in the 
presence of MLM among compounds tested, we assessed in vivo exposure following IP 
injection in mice (Table 6). Despite the two compounds having very similar MLM stability, 
the AUC for 13g was more than double that of 13h. Plasma concentration of 13g exceeded 1 
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μM, the concentration needed for 50% inhibition of ALDEFLUOR (Figure 10A,B), for 
nearly 7 hours. 13h exceeded 0.3 μM, an efficacious dose in the spheroid cisplatin synergy 
assay (Figure 11C), for almost 4 hours.
CONCLUSIONS
In order to explore the structural determinants of ALDH1A isoform selectivity, we generated 
a number of analogs of lead compound 7 guided by a co-crystal structure with 1A1. 
Expedient synthetic routes were developed to allow late-stage diversification at multiple 
sites. The observation that the ortho-methyl group on the N-phenyl was disfavorable to 
binding across the ALDH1A subfamily led to the first potent inhibitors of the three 
ALDH1A isoforms with excellent selectivity over ALDH2 (e.g. 12e). Small structural 
changes led to a new binding mode for compound 13g, explaining SAR trends which did not 
agree with the 1A1 crystal structure for lead compound 7. We demonstrated that remarkable 
changes in ALDH1A isoform-selectivity can be achieved by minor structural changes to the 
N-phenyl substituent, which binds in the narrow lipophilic region of the active site near the 
catalytic cysteine according to the 13g-1A1 structure. In the course of exploring SAR at this 
position we discovered the 1A2 selective compounds 15b and 15f, and the 1A3 selective 
compounds 15g and 15l. Although selectivity within the ALDH1A subfamily is modest, to 
our knowledge, these are the first examples of ALDH1A2 and ALDH1A3 selective 
inhibitors with excellent selectivity against ALDH2. Further efforts to create more potent 
and selective 1A2 and 1A3 inhibitors are underway.
Our preliminary data lead us to hypothesize that ALDEFLUOR activity will be improved by 
inhibiting multiple ALDH1A isoforms simultaneously as compared to an equipotent 1A3 
selective compound (12g, 13g, 13h vs. 15l), even in cell lines which only express detectable 
levels of 1A3. This hypothesis will require more extensive cell testing to confirm our 
preliminary findings. Testing optimized compounds in an expanded panel of cell lines which 
express various ALDH1A isoforms will be necessary and is underway.
Interestingly 12g, 13g, and 13h depleted the CD133+ putative stem cell pool in a dose 
dependent manner, and synergized with cisplatin at a range of concentrations. 13h also 
showed synergy with cisplatin in patient derived ovarian cancer spheroids. Compound 13g 
furthermore shows promising PK properties for in Page 29 of 61 vivo studies, exceeding its 
efficacious cellular concentration in plasma for nearly 7 hours following 10mg/kg IP 
administration in a preliminary study. Xenograft studies on optimal compounds will be 
reported in due course. Future medicinal chemistry development of this series will focus on 
further improving enzymatic and cellular potency and pharmacokinetic properties, as well as 
tuning the selectivity profile among the ALDH1A isoforms in order to generate diverse 
probes for establishing the contribution of individual isoforms to cellular activity.
EXPERIMENTAL SECTION
Crystal Structure Determination
Crystals of ALDH1A1 N121S were grown by equilibrating 4–8 mg/mL ALDH1A1 N121S 
against 100 mM sodium BisTris, pH 6.2–6.5, 6–11% PEG3350, 200 mM NaCl, and 5–10 
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mM YbCl3. The crystal of ALDH1A1 N121S in complex with 7 was prepared by soaking 
approximately 2-week old apo crystals for 6 hr in crystallization solution containing 500 μM 
7 with 1% (v/v) DMSO and 1 mM NAD. The crystal of ALDH1A1 N121S in complex with 
13g was prepared by soaking apo crystals for 1 hr in crystallization solution containing 1 
mM NAD followed by soaking overnight in crystallization solution containing 500 μM 13g 
with 2% (v/v) DMSO and 1 mM NAD. Cryoprotection for flash-freezing was 20% (v/v) 
ethylene glycol in ligand soaking solution. Diffraction data for 7 in complex with 
ALDH1A1 N121S was collected at Beamline 23-ID-D (GM/CA), National Institute of 
General Medicine Sciences and National Cancer Institute of the NIH at APS. Diffraction 
data for 13g in complex with ALDH1A1 N121S was collected at Beamline 19-ID operated 
by the Structural Biology Consortium at the Advance Photon Source (APS), Argonne 
National Laboratory. Diffraction data were indexed, integrated, and scaled using 
HKL3000.58 The CCP4 program suite was used for molecular replacement and refinement.
59
 The Coot molecular graphic application was used for model building.60 The TLSMD 
(translation/libration/screw motion determination) server was used to determine dynamic 
properties of ALDH1A1 N121S.61–62
Protein Purification and Enzymatic Assays—Human ALDH1A1, ALDH1A2, 
ALDH1A3, ALDH2, ALDH1B1, ALDH3A1, ALDH4A1, ALDH5A1 and rat ALDH1L1 
were prepared and purified as previously described. 27, 63–66
Inhibition of ALDH activity by compounds and IC50 curves were determined by measuring 
the formation of NAD(P)H spectrophotometrically at 340 nm (molar extinction coefficient 
of 6200 M−1 cm−1) on the Beckman DU-640 and Spectramax 340PC spectrophotometers 
using purified recombinant enzyme. Reaction components for ALDH1A and ALDH2 assays 
consisted of 100–200 nM enzyme, 200 μM NAD+, 100 μM propionaldehyde, and 1% 
DMSO in 25 mM BES buffer, pH 7.5. For ALDH1B1, the assay included 500 μM NAD+ 
and 200μM propionaldehyde. For ALDH3A1, the assay included 300μM NADP+, 20nM 
enzyme, and 300μM benzaldehyde. For ALDH4A1 and ALDH5A1, the assay included 
1.5mM NAD+, 100nM enzyme, with 20mM propionaldehyde for ALDH4A1 and 2mM 
propionaldehyde for ALDH5A1. For rat ALDH1L1, the assay included 0.5mM NADP+, 
200nM enzyme ad 4mM propionaldehyde. All assays were performed at 25°C and were 
initiated by addition of substrate after a 2 min incubation period. IC50 curves were collected 
for compounds which substantially inhibited ALDH1A activity at 20 μM compound. Data 
were fit to the four parameter EC50 equation using SigmaPlot (v12) and the values represent 
the mean/SEM of three independent experiments (each n=3).
ALDEFLUOR assay
PEO1 and OVCAR5 cells were grown in RPMI 1640 media (Corning) containing 2mM 
glutamine, 2mM sodium pyruvate (PEO1 only, Gibco), 10% FBS (Sigma), and 1X Pen/Strep 
(Gibco). When the cells reached 80% confluency they were harvested by trypsinization and 
assayed for ALDH activity using the aldefluor assay (STEMCELL Technologies). Briefly, 
the cells were washed with PBS before being centrifuged and resuspended in ALDEFLUOR 
buffer. Once the cells were resuspended in ALDEFLUOR buffer, the ALDEFLUOR reagent 
was added. The cells were quickly mixed and evenly distributed into 1.5 mL Eppendorf 
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tubes containing inhibitor or vehicle. The tubes were incubated for 30 minutes at 37 °C. 
Next, the tubes were centrifuged, the buffer containing the ALDEFLUOR reagent was 
removed, and the cells were resuspended in fresh ALDEFLUOR buffer that had been kept 
on ice. The tubes were kept on ice until they were analyzed on an Accuri C6 flow cytometer 
(BD). The percent of control values were calculated using the percentage of ALDEFLUOR 
positive cells for a particular sample and the percentage of ALDEFLUOR positive cells in 
the control sample (vehicle treated). The percentage of ALDEFLUOR positive cells was 
graphed in Prism 7 (GraphPad) and is displayed as mean ± SD. The Two-way ANOVA with 
Tukeys multiple comparison test within Prism 7 (GraphPad) was used to determine 
statistical significance between samples treated with compound or vehicle.
CD133+ cell assay
PEO1 and OVCAR5 cells were grown in RPMI 1640 media (Corning) containing 2mM 
glutamine, 2mM sodium pyruvate (PEO1 only, Gibco)10% FBS (Sigma), and 1X Pen/Strep 
(Gibco). When the cells reached 80% confluency they were harvested by trypsinization, 
washed with PBS, and reseeded in 6-well plates at 1 × 105 cells/well. The cells were allowed 
to recover for 24 h, inhibitor or vehicle was added, and the cells were put back into the 
incubator for 48 h. Following the 48 h incubation, the cells were harvested and counted. An 
equal number of cells were isolated from each sample. The cells were washed with PBS and 
resuspended in fresh PBS. CD133/2-APC antibody (Miltenyi Biotec) was added at a dilution 
of 1:100. The cells were mixed and incubated at room temperature for 10 minutes. Next, ten 
times the volume of PBS was added and the cells were centrifuged. The cells were washed 
with PBS and resuspended in fresh PBS that had been kept on ice. The tubes were kept on 
ice until they could be analyzed on a Cytoflex S flow cytometer (BeckmanCoulter). The 
percentage of CD133 positive cells was graphed in Prism 7 (GraphPad) and is displayed as 
mean ± SD. The Two-way ANOVA with Tukeys multiple comparison test within Prism 7 
(GraphPad) was used to determine statistical significance between samples treated with 
compound or vehicle.
Cell Viability and synergy assays
PEO1 and OVCAR5 cells were grown in RPMI 1640 media (Corning) containing 2mM 
glutamine, 2mM sodium pyruvate (PEO1 only, Gibco)10% FBS (Sigma), and 1X Pen/Strep 
(Gibco). When the cells reached 80% confluency they were harvested by trypsinization, 
washed with PBS, and reseeded in 96-well plates at 4000 cells/well (PEO1) or 1500 cells/
well (OVCAR5). The cells were allowed to recover for 24 h, inhibitor or vehicle was added, 
cisplatin was added, and the cells were put back into the incubator for 72 h. Following the 72 
h incubation, the media was removed and a 1X solution of Cell-Titer Glo 2.0 (Promega) was 
added. The plates were mixed and allowed to incubate at room temperature for 10 min 
before luminescence was read. Normalized viability was calculated by comparing the 
luminesence of drug-treated wells to vehicle treated wells and expressed as a percentage. 
The percentage of viable cells was graphed in Prism 7 and all data are displayed as mean ± 
SD. Synergy was assessed using Chou-Talalay method and the CompuSyn program. 54
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Hanging drop culture for patient derived spheroid formation
Graded patient tumor samples (high grade epithelial stage IIIC or IV, obtained from IRB 
approved protocol, and collected from consented patients) were dissected, digested 
enzymatically using a mixture of Collagenase IV/Dispase, recovered by centrifugation and 
filtered through a 500μm mesh to remove large debris. Resulting patient cells were 
suspended in serum-free medium (SFM) supplemented with 5ng/ml FGF, 5ng/ml EGF, B27, 
1X insulin-transferrin-selenium supplement, 1X nonessential amino acids, antibiotics and 
antimycotics. Cell counts were obtained using a hemocytometer and adjusted such that a 
20μL volume contained 100 cells. Similar to previously established protocol, patient derived 
spheroids were initiated using 100 CD133+ ALDH+ cells per spheroid.55, 57, 67 Spheroids 
were maintained in SFM for a period of 10 days, and imaged using live phase contrast 
microscopy to follow spheroid formation and maintenance.
Drug treatment on patient derived spheroids in hanging drop array culture
Patient derived spheroids were initiated in 384-well hanging drop arrays using 100 cells per 
spheroid. Spheroids were allowed to aggregate and form a 3D microtissue over a period of 
10 days. For drug treatment, a 10X stock of drug was prepared independently, and 2μL of 
drug was added to the 20μL hanging drop containing spheroids, to result in a final 
concentration of 1X. Several drug-dosing regimens were carried out, including cisplatin in 
the range of 1–50μM and ALDH inhibitor 13h in the range of 0.03–30μM.
The effect of drug was assayed on spheroids 72 hours, using the alamarBlue assay to 
determine viability after drug treatment. Control untreated spheroids were maintained for the 
same duration in culture. Cell viability after drug treatment was normalized to untreated 
controls, and quantified. At least 20 spheroids (technical replicates) were assayed per 
experiment, with 5 to 8 biological replicates. Drug-treated spheroids were imaged using 
phase-contrast microscopy to observe morphologic differences in spheroids exposed to drug 
compared with control untreated spheroids.
Metabolic activity in hanging drop ovarian cancer spheroids
AlamarBlue dye (Life Technologies, Carlsbad CA) was added in a 1:10 dilution to 100 cells/
drop spheroids. Following 4 hours of alamarblue addition and incubation, the 384 hanging 
drop array was placed in a fluorescence plate reader (Synergy HT, BioTek Instruments, 
Winooski, VT). Alamarblue fluorescence readings were obtained at 530 nm excitation and 
590 nm emission. To quantify viability within spheroids, alamarblue readings of treated as 
well untreated spheroids were obtained at Day 10, and compared to the untreated Control 
spheroids.
Statistical analysis
Drug viability data were determined and quantified using the alamarBlue assay, as outlined 
previously.55, 57 Briefly, normalized viability was calculated by comparing the alamarBlue 
fluorescence of drug-treated spheroids to control untreated spheroids and expressed as a 
percentage. Statistical analysis was performed using one-way ANOVAs and levels of 
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statistical significance are indicated in the figures. All data are expressed as mean±SEM and 
are an average of at least 5 to 8 independent experiments.
Metabolic Stability in Mouse Liver Microsomes
The metabolic stability was assessed using CD-1 mouse liver microsomes. 1 μM of each 
compound was incubated with 0.5 mg/mL microsomes and 1.7 mM cofactor β-NADPH in 
0.1 M phosphate buffer (pH = 7.4) containing 3.3 mM MgCl2 at 37 °C. The DMSO 
concentration was less than 0.1% in the final incubation system. At 0, 5, 10, 15, 30, 45, and 
60 min of incubation, 40 μL of reaction mixture were taken out, and the reaction is quenched 
by adding 3-fold excess of cold acetonitrile containing 100 ng/mL of internal standard for 
quantification. The collected fractions were centrifuged at 15000rpm for 10 min to collect 
the supernatant for LC−MS/ MS analysis, from which the amount of compound remaining 
was determined. The natural log of the amount of compound remaining was plotted against 
time to determine the disappearance rate and the half-life of tested compounds.
Pharmacokinetic Studies in Mice
All animal experiments in this study were approved by the University of Michigan 
Committee on Use and Care of Animals and Unit for Laboratory Animal Medicine 
(ULAM). The abbreviated pharmacokinetics of compounds 13g and 13h were determined in 
female CD-1 mice following intraperitoneal (ip) injection of 10 mg/kg respectively. 
Compounds were dissolved in the vehicle containing 20% DMSO, 50% PEG-400, and 30% 
PBS. Four blood samples (50 μL) were collected over 7 h (at 0.5h, 2h, 4h, and 7h), 
centrifuged at 35 00 rpm for 10 min, and plasma was frozen at −80˚C for later analysis. 
Plasma concentrations of the compounds were determined by the LC−MS/MS method 
developed and validated for this study. The LC−MS/MS method consisted of a Shimadzu 
HPLC system, and chromatographic separation of tested compound which was achieved 
using a Waters Xbridge-C18 column (5 cm × 2.1 mm, 3.5 μm). An AB Sciex QTrap 4500 
mass spectrometer equipped with an electrospray ionization source (ABI-Sciex, Toronto, 
Canada) in the positive-ion multiple reaction monitoring (MRM) mode was used for 
detection. All pharmacokinetic parameters were calculated by noncompartmental methods 
using WinNonlin, version 3.2 (Pharsight Corporation, Mountain View, CA, USA).
Molecular Modeling
Molecular modeling was performed on a Dell Precision T7400n Mini-Tower, Quad Core 
Xeon Proc X5450 dual processor with 32 nodes computer.
Homology Modeling—Homology models for ALDH1A2 and 1A3 were built on Swiss-
Model Workspace (SMW) using ALDH1A1 PDB (PDB code 5TEI) as a template.68–69 The 
homology modeling on SMW can be briefly described as alignment of a target sequence and 
a template sequence using the “automated mode” since the similarity between ALDH1A 
isoforms are approximately 70%. The target/template alignment along with 3D coordinates 
of the template were used as input for generating an all-atom model for the target sequence 
using ProMod3, a comparative modelling engine. Side chains were remodeled using a 
backbone dependent rotamer library. Finally, the geometry of the resulting model was 
energy minimized by using the force field OpenMM.68–69
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Global and per-residue quality of the model was assessed by the QMEAN scoring function, 
where several statistical potential terms, i.e., geometrical features of the model as well as 
each residue (pairwise atomic distances, torsion angles, solvent accessibility, etc.), are 
compared to statistical parameters obtained from experimental structures.68, 70 The local 
scores are linear combinations of the four statistical potential terms evaluated on a per 
residue basis. Each residue gets a score between 0 and 1, with 1 being the best. To assess the 
overall quality of the model, global QMEAN scores were calculated as a Z-score which 
compares the obtained values to scores calculated from a set of high-resolution X-ray 
structures. GMQE (Global Model Quality Estimation) is another global quality estimation 
which combines properties from the target-template alignment.70 The resulting GMQE score 
is between 0 and 1 and expresses the accuracy of a model built with that alignment and 
template. The quality of the model increases as the number approaches 1. Additionally, the 
model quality was evaluated by a Ramachandran plot within the PROCHECK server.71 
PROCHECK assesses the stereo-chemical quality of a protein structure. A good quality 
model would be expected to have over 90% in the most favored regions.72
Molecular Docking—Molecular docking studies were performed using the HYBRID 
docking program from OpenEye Scientific, Santa Fe, NM against ALDH1A isoforms with 
co-crystal 7 (PDB code 5TEI) or 13g (PDB code 6DUM) as the reference ligands.73 Prior to 
docking, 500 different conformations were generated for each ligand using Omega 
(OpenEye Scientific, Santa Fe, NM), a systematic, knowledge-based conformer generator.74 
HYBRID performs a systematic, exhaustive, non-stochastic examination of poses within the 
protein active site. However, HYBRID reduces this search space based on shape and 
chemical complementarity to reference bound ligands. It treats ligand conformers as rigid 
during the docking process, although ligand flexibility is implicitly included by docking 
multiple conformers of each ligand. The input for HYBRID is a protein structure and a 
multi-conformer representation of the ligand to be docked. In the exhaustive search using the 
Chemical Gaussian Overlay (CGO) scoring function, each ligand conformation is 
systematically rotated and translated within the active site at a resolution of 1 Å. Every pose 
that passes a bump check is scored.73
Chemistry
All reagents were used in the condition received from commercial sources. 1H NMR and 
13C NMR were taken in CDCl3 or DMSO-d6 at room temperature on Varian Inova 400 or 
500 MHz instruments. Reported chemical shifts are expressed in parts per million (ppm) on 
the δ scale from an internal standard of tetramethylsilane (0 ppm). Mass spectrometry data 
were obtained on either an Agilent TOF or Agilent Q-TOF. An Agilent 1100 series HPLC 
with an Agilent Zorbax Eclipse Plus−C18 column was used to determine purity of 
biologically tested compounds. All tested compounds were determined to be >95% pure 
using a 6 minute gradient of 10–90% acetonitrile in water followed by a 2 minute hold at 
90% acetonitrile with detection at 254 nm. Flash chromatographic purifications were 
performed using a Teledyne ISCO Combiflash RF with Redisep Gold RF columns.
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6-((3-Fluorobenzyl)thio)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (7)
To a flask charged with potassium carbonate (1.56 g, 11.3 mmol), 9a (1.46 g, 5.7 mmol), 
and 10 mL DMF was added 3-fluorobenzyl bromide (0.69 mL, 5.7 mmol). After stirring 
under N2 for 16 h at RT the reaction was neutralized with sat. aq. NH4Cl and the mixture 
was diluted with water and extracted 2x with EtOAc. The combined organic portions were 
washed 3x with brine and then dried with sodium sulfate and the solvent removed. The 
crude was purified by flash (50% EtOAc in Hex) yielding the titled compound as a white 
solid (1.26g, 61% yield). HRMS (ESI): m/z 367.1022 [M+H]+. 1H NMR (500 MHz, CDCl3) 
δ 8.40 (br. s, 1H), 8.15 (s, 1H), 7.40 (t, J = 8.30 Hz, 1H), 7.34 (d, J = 7.83 Hz, 1H), 7.31 (t, J 
= 7.83 Hz, 1H), 7.21 (t, J = 7.80 Hz, 1H), 7.18 (d, J = 7.83 Hz, 1H), 7.07 (d, J = 7.34 Hz, 
1H), 7.02 (d, J = 9.29 Hz, 1H), 6.90 (dt, J = 1.96, 8.56 Hz, 1H), 4.28 (d, J = 13.69 Hz, 1H), 
4.31 (d, J = 13.69 Hz, 1H), 2.10 (s, 3H) 13C NMR (126 MHz, CDCl3) δ 162.59 (d, J = 246.5 
Hz), 161.52, 157.71, 153.63, 138.25 (d, J = 7.5 Hz), 136.92, 135.62, 134.42, 131.40, 130.42, 
130.01 (d, J = 8.2 Hz), 129.36, 127.37, 124.82 (d, J = 3.2 Hz), 116.08 (d, J = 21.9 Hz), 
114.54 (d, J = 21.1 Hz), 102.86, 36.55, 17.28. HPLC Purity: 99%.
Method A: General Method for Synthesis of Pyrazolopyrimidinones 10a,b
A solution of the appropriate isothiocyanate (12.9 mmol), and ethyl 5-amino-1H-pyrazole-4-
carboxylate (8a) (12.9 mmol) in 15 mL toluene was refluxed under N2 for 3 h. The thiourea 
intermediate, which precipitated upon cooling to RT, was collected and added to 10 mL 1N 
NaOH and refluxed for 3 h. The product was precipitated by the addition of concentrated 
HCl and collected by filtration.
6-Mercapto-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (10a)
Method A. White solid. 44% yield. 1H NMR (400 MHz, DMSO-d6) δ 13.77 (br. s., 1H), 
13.41 (br. s., 1H), 8.57 (br. s., 1H), 7.19 – 7.31 (m, 3H), 7.09 (d, J = 5.87 Hz, 1H), 1.99 (s, 
3H).
5-Phenyl-6-thioxo-6,7-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (10b)
Method A. White solid. 64% yield. 1H NMR (500 MHz, DMSO-d6) δ 13.73 (s, 1H), 13.37 
(s, 1H), 8.58 (s, 1H), 7.44 (t, J = 7.6 Hz, 2H), 7.37 (t, J = 7.4 Hz, 1H), 7.20 (d, J = 7.7 Hz, 
2H).
6-((3-Fluorobenzyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (11)
Starting from compound 9b the titled compound was synthesized and purified in a similar 
manner to compound 7 and obtained as a white solid. 69% yield. HRMS (ESI): m/z 
353.0867 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 12.54 (br. s., 1H), 8.08 (s, 1H), 7.47 (s, 
3H), 7.30 (s, 2H), 7.14 – 7.22 (m, 1H), 7.06 (d, J = 7.83 Hz, 1H), 7.02 (d, J = 9.39 Hz, 1H), 
6.89 (t, J = 8.60 Hz, 1H), 4.22 – 4.35 (m, 2H), 13C NMR (101 MHz, CDCl3) δ 162.46 (d, J 
= 246.6 Hz), 161.46, 158.34, 153.26, 138.12 (d, J = 7.6 Hz), 135.27, 135.13, 129.98, 129.91 
(d, J = 9.0 Hz), 129.60, 129.27, 124.84 (d, J = 2.9 Hz), 116.07 (d, J = 21.8 Hz), 114.42 (d, J 
= 21.1 Hz), 102.73, 36.68. HPLC Purity: 99%.
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Method B. General Method for Synthesis of N-alkylated Pyrazolopyrimidinones 12a-d, f-h, 
13a-h
To a dry flask charged with 7 or 11 (0.27 mmol) and potassium carbonate (0.55 mmol) under 
N2 was added 2 mL DMF and the appropriate alkyl halide or mesylate (0.34 mmol) by 
syringe. The mixture was heated to 50 °C for 16 h at which point starting material was 
consumed by HPLC. The mixture was diluted with ethyl acetate and washed with water and 
3x with brine. The organic portion was dried over sodium sulfate and the solvent removed. 
The regioisomers were separated by flash (EtOAc in Hex gradient). The 1-alkyl pyrazoles 
(12a-h) eluted more quickly than the 2-alkyl pyrazoles (13a-h). The alkylating reagents used 
are designated below for each compound. All were commercially available except for 
oxetan-3-ylmethyl methanesulfonate which was prepared as previously described.75
6-((3-Fluorobenzyl)thio)-1-methyl-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (12a)
Method B. Methyl iodide. White solid. 43% yield. HRMS (ESI): m/z 381.1179 [M+H]+ 1H 
NMR (400 MHz, DMSO-d6) δ 8.06 (s, 1H), 7.41 (dt, J = 1.20, 6.40 Hz, 2H), 7.31 – 7.38 
(m, 2H), 7.23 – 7.31 (m, 3H), 7.06 (tt, J = 1.60, 8.60 Hz, 1H), 4.38 (d, J = 13.30 Hz, 1H), 
4.43 (d, J = 13.30 Hz, 1H), 3.96 (s, 3H), 1.95 (s, 3H) 13C NMR (126 MHz, CDCl3) δ 162.63 
(d, J = 246.5 Hz), 161.21, 157.07, 151.01, 138.62 (d, J = 7.4 Hz), 136.93, 135.40, 134.49, 
131.41, 130.40, 130.01 (d, J = 8.4 Hz), 129.35, 127.37, 124.67 (d, J = 2.9 Hz), 116.05 (d, J = 
22.0 Hz), 114.54 (d, J = 21.0 Hz), 102.86, 36.56 (d, J = 2.0 Hz), 34.09, 17.29. HPLC Purity: 
97%.
1-(Cyclopropylmethyl)-6-((3-fluorobenzyl)thio)-5-(o-tolyl)-1H-pyrazolo[3,4-
d]pyrimidin-4(5H)-one (12b)
Method B. Cyclopropylmethyl bromide. Colorless oil. 32% yield. HRMS (ESI): m/z 
421.1493 [M+H]+ 1H NMR (500 MHz, CDCl3) δ 8.05 (s, 1H), 7.42 (t, J = 7.80 Hz, 1H), 
7.31 – 7.39 (m, 2H), 7.21 – 7.28 (m, 1H), 7.17 (d, J = 7.34 Hz, 1H), 7.12 (d, J = 7.83 Hz, 
1H), 7.07 (d, J = 9.78 Hz, 1H), 6.94 (dt, J = 2.20, 8.44 Hz, 1H), 4.32 (d, J = 13.69 Hz, 1H), 
4.29 (d, J = 14.18 Hz, 1H), 4.19 (d, J = 7.20 Hz, 2H), 2.12 (s, 3H), 1.32 – 1.44 (m, 1H), 0.62 
(td, J = 5.50, 7.80 Hz, 2H), 0.44 (dt, J = 4.80, 5.50 Hz, 2H) 13C NMR (126 MHz, CDCl3) δ 
162.66 (d, J = 246.7 Hz), 160.99, 157.09, 150.50, 138.64 (d, J = 7.4 Hz), 136.96, 135.33, 
134.53, 131.37, 130.36, 130.01 (d, J = 8.2 Hz), 129.34, 127.33, 124.45 (d, J = 2.7 Hz), 
115.81 (d, J = 22.1 Hz), 114.47 (d, J = 21.0 Hz), 102.82, 52.05, 36.49 (d, J = 1.9 Hz), 17.33, 
11.16, 3.97. HPLC Purity: 96%.
6-((3-Fluorobenzyl)thio)-1-(oxetan-3-yl)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
(12c)
Method B. 3-Bromooexetane. White solid. 18% yield. HRMS (ESI): m/z 423.1292 [M+H]+ 
1H NMR (500 MHz, CDCl3) δ 8.14 (s, 1H), 7.41 – 7.46 (m, 1H), 7.32 – 7.39 (m, 2H), 7.24 
– 7.29 (m, 1H), 7.11 – 7.17 (m, 2H), 7.06 – 7.10 (m, 1H), 6.95 (dt, J = 2.20, 8.44 Hz, 1H), 
5.91 – 5.99 (m, 1H), 5.28 – 5.35 (m, 2H), 5.04 – 5.09 (m, 2H), 4.30 (d, J = 13.69 Hz, 1H), 
4.34 (d, J = 13.69 Hz, 1H), 2.10 (s, 1H) 13C NMR (126 MHz, CDCl3) δ 162.71 (d, J = 246.9 
Hz), 161.93, 156.91, 151.04, 138.31 (d, J = 7.6 Hz), 136.85, 136.37, 134.35, 131.51, 130.55, 
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130.10 (d, J = 8.4 Hz), 129.26, 127.47, 124.57 (d, J = 2.9 Hz), 115.92 (d, J = 22.0 Hz), 
114.66 (d, J = 21.1 Hz), 103.38, 76.85, 50.69, 36.62, 17.32. HPLC Purity: 98%.
6-((3-Fluorobenzyl)thio)-1-(oxetan-3-ylmethyl)-5-(o-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-
one (12d)
Method B. Oxetan-3-ylmethyl methanesulfonate. White crystalline solid. 42% yield. HRMS 
(ESI): m/z 437.1449 [M+H]+ 1H NMR (500 MHz, CDCl3) δ 8.03 (s, 1H), 7.42 – 7.47 (m, 
1H), 7.33 – 7.40 (m, 2H), 7.25 – 7.31 (m, 1H), 7.17 (d, J = 7.34 Hz, 1H), 7.14 (d, J = 7.34 
Hz, 1H), 7.06 – 7.11 (m, 1H), 6.97 (dt, J = 2.45, 8.31 Hz, 1H), 4.86 (dt, J = 1.47, 7.09 Hz, 
2H), 4.59 – 4.66 (m, 4H), 4.35 (d, J = 13.69 Hz, 1H), 4.31 (d, J = 14.18 Hz, 1H), 3.52 – 3.61 
(m, 1H), 2.12 (s, 3H) 13C NMR (126 MHz, CDCl3) δ 162.68 (d, J = 246.7 Hz), 161.69, 
156.89, 150.99, 138.43 (d, J = 7.5 Hz), 136.90, 135.82, 134.41, 131.44, 130.46, 130.08 (d, J 
= 8.2 Hz), 129.28, 127.40, 124.50 (d, J = 2.9 Hz), 115.86 (d, J = 22.0 Hz), 114.58 (d, J = 
21.3 Hz), 102.85, 74.85, 74.77, 49.40, 36.64 (d, J = 1.9 Hz), 35.21, 17.32. HPLC Purity: 
99%.
Method C. General Synthesis of substituted pyrazolothiopyrimidinones 12e, 15a-i from 14
To a dry flask under N2 charged with 14 (0.24 mmol) and 2 mL dry DMF was added the 
appropriate amine (0.24 mmol) by syringe. The reaction was stirred at RT for 1hr and then 
cooled to 0°C. 60 wt.% NaH in mineral oil(0.24 mmol) was added and the flask was stirred 
at 0C for 20min then allowed to warm to RT and stirred for 3 h. The flask was once again 
cooled to 0°C and 3-fluorobenzyl bromide (0.24 mmol) was added by syringe. The mixture 
was stirred at 0°C for 30 min at which point the reaction was complete by HPLC. The 
reaction was diluted with 10 mL water and extracted 2x with 10 mL EtOAc. The combined 
organic portion was washed 3x with brine, dried over sodium sulfate and the solvent 
removed. The crude product was purified by flash (0–100% EtOAc in Hexanes).
6-((3-Fluorobenzyl)thio)-1-methyl-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (12e)
Method C. White crystalline solid. 84 % yield. HRMS (ESI): m/z 367.1023 [M+H]+ 1H 
NMR (500 MHz, CDCl3) δ 8.03 (s, 1H), 7.47 – 7.58 (m, 3H), 7.22 – 7.30 (m, 3H), 7.13 (d, 
J = 7.83 Hz, 1H), 7.09 (d, J = 9.78 Hz, 1H), 6.95 (dt, J = 2.20, 8.44 Hz, 1H), 4.34 (s, 2H), 
4.01 (s, 3H) 13C NMR (126 MHz, CDCl3) δ 162.67 (d, J = 246.6 Hz), 161.31, 157.68, 
150.89, 138.47 (d, J = 7.4 Hz), 135.50, 135.42, 130.11, 130.06 (d, J = 8.3 Hz), 129.75, 
129.36, 124.76 (d, J = 3.1 Hz), 116.15 (d, J = 21.9 Hz), 114.61 (d, J = 21.0 Hz), 102.95, 
36.88, 34.12. HPLC Purity: 98%.
1-(Cyclopropylmethyl)-6-((3-fluorobenzyl)thio)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-
one (12f)
Method B. Cyclopropylmethyl bromide. White Solid. 47.7 % yield. HRMS (ESI): m/z 
407.1335 [M+H]+ 1H NMR (400 MHz, CDCl3) δ 8.05 (s, 1H), 7.48 – 7.57 (m, 3H), 7.20 – 
7.33 (m, 3H), 7.12 (d, J = 7.83 Hz, 1H), 7.08 (d, J = 9.39 Hz, 1H), 6.95 (t, J = 8.41 Hz, 1H), 
4.31 (s, 2H), 4.19 (d, J = 7.04 Hz, 2H), 1.38 (s, 1H), 0.54 – 0.69 (m, 2H), 0.36 – 0.50 (m, 
2H) 13C NMR (101 MHz, CDCl3) δ 162.69 (d, J = 246.7 Hz), 161.07, 157.71, 150.37, 
138.46 (d, J = 7.6 Hz), 135.53, 135.35 (d, J = 3.7 Hz), 130.07, 130.05 (d, J = 8.1 Hz), 
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129.72, 129.35, 124.55 (d, J = 2.9 Hz), 115.92 (d, J = 21.9 Hz), 114.54 (d, J = 21.3 Hz), 
102.91, 52.05, 36.82, 11.22, 3.98. HPLC Purity: 99%.
6-((3-Fluorobenzyl)thio)-1-(oxetan-3-yl)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
(12g)
Method B. 3-bromooexetane. White solid. 15.5 % yield. HRMS (ESI): m/z 409.1131 [M+H]
+
 
1H NMR (500 MHz, CDCl3) δ 8.13 (s, 1H), 7.50 – 7.57 (m, 3H), 7.21 – 7.31 (m, 3H), 
7.12 (d, J = 7.83 Hz, 1H), 7.08 (d, J = 9.29 Hz, 1H), 6.92 – 6.99 (m, 1H), 5.94 (quin, J = 
7.21 Hz, 1H), 5.30 (t, J = 6.36 Hz, 2H), 5.06 (t, J = 7.09 Hz, 2H), 4.33 (s, 2H) 13C NMR 
(126 MHz, CDCl3) δ 162.71 (d, J = 246.6 Hz), 161.98, 157.48, 150.90, 138.14 (d, J = 7.4 
Hz), 136.33, 135.33, 130.22, 130.12 (d, J = 8.3 Hz), 129.82, 129.25, 124.64 (d, J = 2.9 Hz), 
115.99 (d, J = 22.1 Hz), 114.69 (d, J = 21.1 Hz), 103.47, 76.81, 50.75, 36.91. HPLC Purity: 
96%.
6-((3-Fluorobenzyl)thio)-1-(oxetan-3-ylmethyl)-5-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-
one (12h)
Method B. Oxetan-3-ylmethyl methanesulfonate. White solid. 32.5 % yield. HRMS (ESI): 
m/z 423.1289 [M+H]+ 1H NMR (500 MHz, CDCl3) δ 8.00 (s, 1H), 7.48 – 7.56 (m, 3H), 
7.23 – 7.31 (m, 3H), 7.14 (d, J = 7.83 Hz, 1H), 7.08 (d, J = 9.78 Hz, 1H), 6.92 – 6.98 (m, 
1H), 4.83 (t, J = 7.09 Hz, 2H), 4.62 (d, J = 7.34 Hz, 2H), 4.60 (t, J = 6.10 Hz, 2H), 4.32 (s, 
2H), 3.48 – 3.59 (m, 1H) 13C NMR (126 MHz, CDCl3) δ 162.59 (d, J = 246.6 Hz), 161.67, 
157.39, 150.77, 138.22 (d, J = 7.6 Hz), 135.68, 135.34, 130.05, 130.2 (d, J = 7.6) 129.99, 
129.67, 129.21, 124.51 (d, J = 3.0 Hz), 115.84 (d, J = 22.0 Hz), 114.52 (d, J = 21.0 Hz), 
102.84, 74.67, 49.29, 36.85, 35.15. HPLC Purity: 99%.
6-((3-Fluorobenzyl)thio)-2-methyl-5-(o-tolyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (13a)
Method B. Methyl iodide. Colorless Oil. 27% yield. HRMS (ESI): m/z 381.1179 [M+H]+ 
1H NMR (500 MHz, CDCl3) δ 8.03 (s, 1H), 7.40 (t, J = 7.58 Hz, 1H), 7.29 – 7.36 (m, 2H), 
7.19 – 7.25 (m, 1H), 7.17 (d, J = 7.83 Hz, 1H), 7.13 (d, J = 7.83 Hz, 1H), 7.07 (d, J = 9.78 
Hz, 1H), 6.91 (dt, J = 2.00, 8.30 Hz, 1H), 4.33 – 4.42 (m, 2H), 4.07 (s, 3H), 2.10 (s, 3H) 13C 
NMR (126 MHz, CDCl3) δ 162.61 (d, J = 246.1 Hz), 159.88, 158.40, 157.99, 138.73 (d, J = 
7.4 Hz), 137.12, 134.53, 131.25, 130.26, 129.89 (d, J = 8.5 Hz), 129.59, 129.31, 127.20, 
124.93 (d, J = 2.9 Hz), 116.09 (d, J = 21.6 Hz), 114.34 (d, J = 21.1 Hz), 104.89, 40.29, 36.60 
(d, J = 2.1 Hz), 17.29. HPLC Purity: 99%.
2-(Cyclopropylmethyl)-6-((3-fluorobenzyl)thio)-5-(o-tolyl)-2H-pyrazolo[3,4-
d]pyrimidin-4(5H)-one (13b)
Method B. Cyclopropylmethyl bromide. White Crystalline solid. 38% yield. HRMS (ESI): 
m/z 421.1492 [M+H]+ 1H NMR (500 MHz, CDCl3) δ 8.21 (s, 1H), 7.40 (t, J = 7.34 Hz, 
1H), 7.28 – 7.36 (m, 2H), 7.19 – 7.25 (m, 1H), 7.17 (d, J = 7.83 Hz, 1H), 7.12 (d, J = 7.83 
Hz, 1H), 7.06 (d, J = 9.78 Hz, 1H), 6.91 (t, J = 8.31 Hz, 1H), 4.41 (d, J = 14.18 Hz, 1H), 
4.38 (d, J = 14.20 Hz, 1H), 4.13 (d, J = 6.85 Hz, 2H), 2.12 (s, 3H), 1.36 – 1.47 (m, 1H), 0.69 
– 0.78 (m, 2H), 0.42 – 0.49 (m, 2H) 13C NMR (126 MHz, CDCl3) δ 162.58 (d, J = 246.2 
Hz), 159.74, 158.16, 158.10, 138.60 (d, J = 7.3 Hz), 137.13, 134.55, 131.22, 130.21, 129.87 
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(d, J = 8.4 Hz), 129.58, 127.85, 127.17, 124.90 (d, J = 3.1 Hz), 116.08 (d, J = 21.9 Hz), 
114.32 (d, J = 21.2 Hz), 104.54, 58.20, 36.64, 17.30, 10.71, 4.19. HPLC Purity: 97%.
6-((3-Fluorobenzyl)thio)-2-(oxetan-3-yl)-5-(o-tolyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
(13c)
Method B. 3-Bromooexetane. White solid. 15% yield. HRMS (ESI): m/z 423.1295 [M+H]+ 
1H NMR (500 MHz, CDCl3) δ 8.21 (s, 1H), 7.39 – 7.45 (m, 1H), 7.30 – 7.37 (m, 2H), 7.23 
(dt, J = 5.87, 7.83 Hz, 1H), 7.15 – 7.19 (m, 1H), 7.12 (d, J = 7.83 Hz, 1H), 7.04 – 7.09 (m, 
1H), 6.92 (dt, J = 1.96, 8.56 Hz, 1H), 5.53 – 5.62 (m, 1H), 5.23 (t, J = 6.60 Hz, 2H), 5.10 (t, 
J = 7.34 Hz, 2H), 4.38 – 4.46 (m, 2H), 2.11 (s, 3H) 13C NMR (126 MHz, CDCl3) δ 162.70 
(d, J = 246.7 Hz), 160.89, 158.58, 157.91, 138.34 (d, J = 7.8 Hz), 137.11, 134.40, 131.36, 
130.41, 130.00 (d, J = 8.2 Hz), 129.58, 128.09, 127.31, 124.97 (d, J = 3.2 Hz), 116.18 (d, J = 
22.2 Hz), 114.51 (d, J = 21.0 Hz), 105.25, 76.81 (d, J = 2.7 Hz), 56.83, 36.87, 17.34. HPLC 
Purity: 96%.
6-((3-Fluorobenzyl)thio)-2-(oxetan-3-ylmethyl)-5-(o-tolyl)-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-
one (13d)
Method B. Oxetan-3-ylmethyl methanesulfonate. Colorless oil. 24.3 % yield. HRMS (ESI): 
m/z 437.1449 [M+H]+ 1H NMR (500 MHz, CDCl3) δ 8.07 (s, 1H), 7.38 – 7.44 (m, 1H), 
7.29 – 7.37 (m, 2H), 7.22 (dt, J = 6.11, 7.95 Hz, 1H), 7.16 (d, J = 7.34 Hz, 1H), 7.10 (d, J = 
7.83 Hz, 1H), 7.05 (dd, J = 1.96, 9.78 Hz, 1H), 6.91 (dt, J = 2.45, 8.31 Hz, 1H), 4.88 (t, J = 
7.09 Hz, 2H), 4.59 (d, J = 7.83 Hz, 2H), 4.55 (t, J = 6.36 Hz, 2H), 4.35 – 4.43 (m, 2H), 3.62 
– 3.71 (m, 1H), 2.11 (s, 3H) 13C NMR (126 MHz, CDCl3) δ 162.66 (d, J = 246.2 Hz), 
160.42, 158.56, 157.96, 138.42 (d, J = 7.7 Hz), 137.13, 134.45, 131.32, 130.36, 129.96 (d, J 
= 8.3 Hz), 129.57, 128.70, 127.28, 124.95 (d, J = 2.6 Hz), 116.18 (d, J = 21.9 Hz), 114.45 
(d, J = 21.1 Hz), 104.89, 74.48 (d, J = 2.7 Hz), 55.85, 36.79, 35.36, 17.35. HPLC Purity: 
99%.
6-((3-Fluorobenzyl)thio)-2-methyl-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (13e)
Method B. Methyl Iodide. White solid. 24.0 % yield. HRMS (ESI): m/z 367.1021 [M+H]+ 
1H NMR (500 MHz, CDCl3) δ 8.02 (s, 1H), 7.46 – 7.56 (m, 3H), 7.26 – 7.31 (m, 2H), 7.23 
(q, J = 7.34 Hz, 1H), 7.14 (d, J = 7.83 Hz, 1H), 7.08 (d, J = 9.29 Hz, 1H), 6.92 (t, J = 8.07 
Hz, 1H), 4.39 (s, 2H), 4.07 (s, 3H) 13C NMR (126 MHz, CDCl3) δ 162.64 (d, J = 246.3 Hz), 
159.88, 158.52, 158.23, 138.61 (d, J = 7.6 Hz), 135.54, 129.91 (d, J = 8.3 Hz), 129.91, 
129.57, 129.54, 129.25, 124.98 (d, J = 3.2 Hz), 116.17 (d, J = 21.9 Hz), 114.38 (d, J = 21.3 
Hz), 104.95, 40.28, 36.90. HPLC Purity: 96%.
2-(Cyclopropylmethyl)-6-((3-fluorobenzyl)thio)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-
one (13f)
Method B. Cyclopropylmethyl bromide. White Solid. 36.8 % yield. HRMS (ESI): m/z 
407.1334 [M+H]+ 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.42 – 7.58 (m, 3H), 7.27 (d, 
J = 4.30 Hz, 2H), 7.16 – 7.24 (m, 1H), 7.11 (d, J = 7.43 Hz, 1H), 7.06 (d, J = 9.78 Hz, 1H), 
6.90 (t, J = 8.41 Hz, 1H), 4.39 (s, 2H), 4.12 (d, J = 7.04 Hz, 2H), 1.34 – 1.49 (m, 1H), 0.72 
(d, J = 7.83 Hz, 2H), 0.44 (d, J = 4.30 Hz, 2H) 13C NMR (101 MHz, CDCl3) δ 162.7, 159.8, 
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158.8, 158.0, 138.5, 135.6, 130.0, 129.9, 129.6, 129.6, 127.9, 125.0, 116.2, 114.4, 104.7, 
58.3, 37.0, 10.5, 4.3. HPLC Purity: 99%.
6-((3-Fluorobenzyl)thio)-2-(oxetan-3-yl)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
(13g)
Method B. 3-bromooexetane. White solid. 21.6 % yield. HRMS (ESI): m/z 409.1130 [M+H]
+
 
1H NMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 7.46 – 7.54 (m, 3H), 7.26 – 7.31 (m, 2H), 
7.19 – 7.25 (m, 1H), 7.12 (d, J = 7.34 Hz, 1H), 7.06 (d, J = 9.78 Hz, 1H), 6.92 (dt, J = 1.71, 
8.44 Hz, 1H), 5.56 (quin, J = 6.97 Hz, 1H), 5.21 (t, J = 6.60 Hz, 2H), 5.07 (t, J = 7.34 Hz, 
2H), 4.42 (s, 2H) 13C NMR (126 MHz, CDCl3) δ 162.71 (d, J = 246.3 Hz), 160.83, 158.50, 
158.42, 138.22 (d, J = 7.4 Hz), 135.42, 130.09, 130.02 (d, J = 6.8Hz), 129.68, 129.58, 
128.18, 125.05 (d, J = 3.0 Hz), 116.26 (d, J = 21.9 Hz), 114.55 (d, J = 21.1 Hz), 105.26, 
76.82, 56.81, 37.17. HPLC Purity: 96%.
6-((3-Fluorobenzyl)thio)-2-(oxetan-3-ylmethyl)-5-phenyl-2H-pyrazolo[3,4-d]pyrimidin-4(5H)-
one (13h)
Method B. Oxetan-3-ylmethyl methanesulfonate. White solid. 22.5 % yield. HRMS (ESI): 
m/z 423.1286 [M+H]+ 1H NMR (500 MHz, CDCl3) δ 8.07 (s, 1H), 7.47 – 7.54 (m, 3H), 
7.25 – 7.30 (m, 2H), 7.19 – 7.25 (m, 1H), 7.11 (d, J = 7.34 Hz, 1H), 7.05 (d, J = 9.29 Hz, 
1H), 6.92 (dt, J = 1.47, 8.31 Hz, 1H), 4.86 (t, J = 7.09 Hz, 2H), 4.57 (d, J = 7.34 Hz, 2H), 
4.54 (t, J = 6.11 Hz, 2H), 4.38 (s, 2H), 3.58 – 3.70 (m, 1H) 13C NMR (126 MHz, CDCl3) δ 
162.63 (d, J = 246.5 Hz), 160.34, 158.48, 158.36, 138.26 (d, J = 7.5 Hz), 135.42, 129.98, 
129.95 (d, J = 7.8 Hz), 129.59, 129.52, 128.68, 124.98 (d, J = 2.9 Hz), 116.21 (d, J = 21.9 
Hz), 114.45 (d, J = 21.0 Hz), 104.90, 74.41, 55.76, 37.03, 35.31. HPLC Purity: 99%.
Ethyl 5-isothiocyanato-1-methyl-1H-pyrazole-4-carboxylate (14)
To a dry flask under N2 at 0°C charged with 60 wt.% NaH in mineral oil (296 mg, 7.39 
mmol) and 8b (500 mg, 2.96 mmol) was added 10 mL THF. The mixture was stirred for 10 
min at which point CS2 (1.8 mL, 29.6 mmol) was added by syringe. The mixture was 
allowed warm to room temperature then heated to 40°C and stirred for 3 h. After cooling the 
flask to 0°C, iodine was added portion-wise over 10 min. The mixture was stirred for 1 h at 
0°C then 30 mL diethyl ether was added and the precipitate was filtered off. The filtrate was 
washed 3x with 1N HCl, 1x with brine and the organic portion was dried over sodium 
sulfate and the solvent removed yielding a reddish black solid. The crude product was 
purified by flash (0–30% EA in Hex) yielding the titled compound as a yellow solid (460 
mg, 2.18 mmol, 74% yield). MS (ESI): m/z 212.0 [M+H]+ 1H NMR (400 MHz, CDCl3) δ 
7.81 (s, 1H), 4.25 – 4.44 (m, 2H), 3.80 (s, 3H), 1.30 – 1.44 (m, 3H).
5-(2-Chlorophenyl)-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
(15a)
Method C. White crystalline solid. 83% yield. HRMS (ESI): m/z 401.0629 [M+H]+ 1H 
NMR (500 MHz, CDCl3) δ 8.04 (s, 1H), 7.58 (dd, J = 1.47, 7.83 Hz, 1H), 7.48 (dt, J = 1.71, 
7.70 Hz, 1H), 7.43 (dt, J = 1.47, 7.58 Hz, 1H), 7.33 (d, J = 7.83 Hz, 1H), 7.23 – 7.30 (m, 
1H), 7.15 (d, J = 7.34 Hz, 1H), 7.10 (d, J = 9.78 Hz, 1H), 6.95 (dt, J = 1.96, 8.31 Hz, 1H), 
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4.32 – 4.42 (m, 2H), 4.01 (s, 3H) 13C NMR (126 MHz, CDCl3) δ 162.67 (d, J = 246.8 Hz), 
160.82, 156.77, 150.91, 138.29 (d, J = 7.3 Hz), 135.54, 133.78, 133.22, 131.56, 131.21, 
130.73, 130.05 (d, J = 8.5 Hz), 128.07, 124.69 (d, J = 2.9 Hz), 116.07 (d, J = 22.1 Hz), 
114.63 (d, J = 21.0 Hz), 102.72, 36.59, 34.15. HPLC Purity: 99%.
5-(3-Chlorophenyl)-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
(15b)
Method C. White crystalline solid. 44% yield. HRMS (ESI): m/z 401.0629 [M+H]+ 1H 
NMR (500 MHz, CDCl3) δ 8.03 (s, 1H), 7.51 (td, J = 1.60, 8.00 Hz, 1H), 7.47 (t, J = 8.00 
Hz, 1H), 7.26 – 7.32 (m, 2H), 7.18 (td, J = 1.53, 7.70 Hz, 1H), 7.15 (d, J = 7.83 Hz, 1H), 
7.11 (td, J = 2.08, 9.54 Hz, 1H), 6.98 (dt, J = 2.69, 8.44 Hz, 1H), 4.32 – 4.41 (m, 2H), 4.02 
(s, 3H) 13C NMR (126 MHz, CDCl3) δ 162.70 (d, J = 246.8 Hz), 160.84, 157.42, 150.77, 
138.20 (d, J = 7.6 Hz), 136.53, 135.47, 135.27, 130.66, 130.47, 130.15 (d, J = 8.1 Hz), 
129.77, 127.77, 124.78 (d, J = 3.2 Hz), 116.19 (d, J = 21.7 Hz), 114.74 (d, J = 21.0 Hz), 
102.80, 36.93, 34.18. HPLC Purity: 98%.
5-(4-Chlorophenyl)-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
(15c)
Method C. White crystalline solid. 44% yield. HRMS (ESI): m/z 401.0629 [M+H]+ 1H 
NMR (500 MHz, CDCl3) δ 8.02 (s, 1H), 7.49 (d, J = 8.31 Hz, 2H), 7.24 – 7.30 (m, 1H), 
7.20 (d, J = 8.31 Hz, 2H), 7.13 (d, J = 7.34 Hz, 1H), 7.09 (d, J = 9.78 Hz, 1H), 6.96 (dt, J = 
2.45, 8.31 Hz, 1H), 4.34 (s, 2H), 4.01 (s, 3H) 13C NMR (126 MHz, CDCl3) δ 162.69 (d, J = 
246.7 Hz), 160.96, 157.53, 150.81, 138.22 (d, J = 7.6 Hz), 136.33, 135.44, 133.89, 130.75, 
130.17, 130.11, 124.76 (d, J = 2.9 Hz), 116.16 (d, J = 22.1 Hz), 114.73 (d, J = 21.0 Hz), 
102.81, 36.92, 34.16. HPLC Purity: 99%.
6-((3-Fluorobenzyl)thio)-5-(2-fluorophenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
(15d)
Method C. White crystalline solid. 70% yield. HRMS (ESI): m/z 385.0932 [M+H]+ 1H 
NMR (500 MHz, CDCl3) δ 8.03 (s, 1H), 7.57 – 7.49 (m, 1H), 7.36 – 7.20 (m, 4H), 7.14 (d, 
J = 7.6 Hz, 1H), 7.10 (d, J = 9.5 Hz, 1H), 6.96 (td, J = 8.4, 2.5 Hz, 1H), 4.40 (d, J = 13.7 Hz, 
1H), 4.34 (d, J = 13.6 Hz, 1H), 4.01 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 162.70 (d, J = 
247.0 Hz), 161.09, 158.28 (d, J = 253.4 Hz), 156.94, 150.92, 138.20 (d, J = 7.6 Hz), 135.52, 
132.33 (d, J = 8.0 Hz), 131.24, 130.12 (d, J = 8.5 Hz), 125.05 (d, J = 3.9 Hz), 124.75 (d, J = 
3.1 Hz), 123.11 (d, J = 14.1 Hz), 117.03 (d, J = 19.5 Hz), 116.15 (d, J = 22.2 Hz), 114.71 (d, 
J = 21.0 Hz), 102.69, 36.73, 34.18. HPLC Purity: 98%.
6-((3-Fluorobenzyl)thio)-5-(2-methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-
one (15e)
Method C. White crystalline solid. 19% yield. HRMS (ESI): m/z 397.1127 [M+H]+ (400 
MHz, CDCl3) δ 8.02 (s, 1H), 7.49 (t, J = 8.02 Hz, 1H), 7.22 – 7.29 (m, 1H), 7.19 (d, J = 
7.83 Hz, 1H), 7.02 – 7.16 (m, 4H), 6.94 (t, J = 8.22 Hz, 1H), 4.33 (s, 2H), 3.99 (s, 3H), 3.78 
(s, 3H) 13C NMR (101 MHz, CDCl3) δ 162.64 (d, J = 246.3 Hz), 161.76, 157.31, 155.40, 
151.04, 138.76 (d, J = 7.6 Hz), 135.39, 131.80, 130.64, 129.92 (d, J = 8.4 Hz), 124.70 (d, J = 
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2.9 Hz), 123.89, 121.08, 116.00 (d, J = 21.9 Hz), 114.44 (d, J = 21.0 Hz), 112.34, 102.95, 
55.82, 36.48, 34.06. HPLC Purity: 99%.
6-((3-Fluorobenzyl)thio)-5-(3-methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-
one (15f)
Method C. White Solid. 80% yield. HRMS (ESI): m/z 397.1125 [M+H]+ 1H NMR (400 
MHz, CDCl3) δ 7.99 (s, 1H), 7.41 (t, J = 8.22 Hz, 1H), 7.21 – 7.30 (m, 1H), 7.07 – 7.17 (m, 
2H), 7.04 (dd, J = 2.35, 8.22 Hz, 1H), 6.90 – 6.98 (m, 1H), 6.85 (dd, J = 0.78, 7.83 Hz, 1H), 
6.80 (d, J = 1.96 Hz, 1H), 4.33 (s, 2H), 3.99 (s, 3H), 3.80 (s, 3H) 13C NMR (101 MHz, 
CDCl3) δ 162.55 (d, J = 246.6 Hz), 161.20, 160.39, 157.50, 150.73, 138.41 (d, J = 7.5 Hz), 
136.38, 135.24, 130.29, 129.97 (d, J = 8.3 Hz), 124.72 (d, J = 3.0 Hz), 121.31, 116.06 (d, J = 
21.8 Hz), 115.82, 114.83, 114.48 (d, J = 21.1 Hz), 102.79, 55.39, 36.74, 34.04. HPLC 
Purity: 97%.
6-((3-Fluorobenzyl)thio)-5-(4-methoxyphenyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-
one (15g)
Method C. White needles. 47% yield. HRMS (ESI): m/z 397.1123 [M+H]+ 1H NMR (400 
MHz, CDCl3) δ 8.01 (s, 1H), 7.22 – 7.30 (m, 1H), 7.07 – 7.19 (m, 4H), 6.98 – 7.04 (m, 2H), 
6.95 (dt, J = 2.35, 8.41 Hz, 1H), 4.32 (s, 2H), 4.00 (s, 3H), 3.85 (s, 3H) 13C NMR (101 
MHz, CDCl3) δ 162.64 (d, J = 246.4 Hz), 161.92, 160.63, 157.91, 150.86, 138.52 (d, J = 7.4 
Hz), 135.38, 130.40, 130.00, 127.75, 124.76 (d, J = 2.7 Hz), 116.16 (d, J = 22.6 Hz), 114.96, 
114.56 (d, J = 21.0 Hz), 102.91, 55.45, 36.93, 34.14. HPLC Purity: 96%.
6-((3-Fluorobenzyl)thio)-1-methyl-5-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
(15h)
Method C. White solid. 64 % yield. HRMS (ESI): m/z 368.0972 [M+H]+ (500 MHz, 
CDCl3) δ 8.72 (d, J = 4.40 Hz, 1H), 8.52 (s, 1H), 7.97 (s, 1H), 7.63 (d, J = 8.31 Hz, 1H), 
7.45 (dd, J = 4.89, 7.83 Hz, 1H), 7.21 – 7.30 (m, 1H), 7.12 (d, J = 7.34 Hz, 1H), 7.07 (d, J = 
9.78 Hz, 1H), 6.94 (t, J = 8.30 Hz, 1H), 4.37 (d, J = 14.18 Hz, 1H), 4.33 (d, J = 14.18 Hz, 
1H), 4.00 (s, 3H) 13C NMR (126 MHz, CDCl3) δ 162.54 (d, J = 246.9 Hz), 160.65, 157.29, 
150.83, 150.64, 150.08, 137.96 (d, J = 7.6 Hz), 137.13, 135.25, 132.31, 130.05 (d, J = 8.2 
Hz), 124.66 (d, J = 3.2 Hz), 124.07, 116.02 (d, J = 21.9 Hz), 114.64 (d, J = 21.0 Hz), 102.54, 
36.80, 34.09. HPLC Purity: 99%.
6-((3-Fluorobenzyl)thio)-1-methyl-5-(pyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
(15i)
Method C. Off white solid. 62% yield. HRMS (ESI): m/z 368.0974 [M+H]+ 1H NMR (500 
MHz, CDCl3) δ 8.82 (d, J = 4.89 Hz, 2H), 8.00 (s, 1H), 7.26 – 7.32 (m, 1H), 7.25 (d, J = 
5.38 Hz, 2H), 7.13 (d, J = 7.83 Hz, 1H), 7.09 (d, J = 9.78 Hz, 1H), 6.96 (dt, J = 2.45, 8.31 
Hz, 1H), 4.37 (s, 2H), 4.01 (s, 3H) 13C NMR (101 MHz, CDCl3) δ 162.48 (d, J = 246.8 Hz), 
162.30, 159.50, 156.74, 151.49, 150.51, 143.30, 137.86 (d, J = 7.5 Hz), 135.19, 130.03 (d, J 
= 8.3 Hz), 124.62 (d, J = 3.0 Hz), 124.20, 115.96 (d, J = 22.1 Hz), 114.63 (d, J = 21.0 Hz), 
102.45, 36.28, 34.06 (d, J = 4.9 Hz). HPLC Purity: 99%.
Huddle et al. Page 24
J Med Chem. Author manuscript; available in PMC 2019 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Method D. General Synthesis of substituted pyrazolothiopyrimidinones 15j-l from 14
To a dry flask under N2 charged with 14 (0.24 mmol) and 2 mL dry DMF was added the 
appropriate amine (0.24 mmol) by syringe. The reaction was stirred at RT for 1 h and then 
cooled to 0°C. 60 wt. % NaH in mineral oil (0.71 mmol) was added and the flask was stirred 
at 0°C for 20 min then allowed to warm to RT and stirred for 3 h. The reaction was 
quenched with sat. aq. NH4Cl and extracted 2x with ethyl acetate. The combined organics 
were dried with sodium sulfate and the solvent removed. The residue was dissolved in 2 mL 
DMF and 3-fluorobenzyl bromide (0.03 mL, 0.24 mmol), sodium bicarbonate (80 mg, 0.95 
mmol) were added. The mixture was stirred at RT overnight at which point the reaction was 
complete by HPLC. The mixture was diluted with water and extracted 2x with EtOAc. The 
combined organics were washed 3x with brine, dried over sodium sulfate, and the solvent 
removed. The crude product was purified by flash chromatography (0–100% EtOAc in Hex) 
yielding the titled compounds.
6-((3-Fluorobenzyl)thio)-1-methyl-5-(pyridin-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one 
(15j)
Method D. White needles. 40% yield. HRMS (ESI): m/z 368.0977 [M+H]+ 1H NMR (500 
MHz, CDCl3) δ 8.69 (dd, J = 1.47, 4.89 Hz, 1H), 8.03 (s, 1H), 7.92 (dt, J = 1.96, 7.58 Hz, 
1H), 7.44 – 7.49 (m, 1H), 7.38 (d, J = 7.83 Hz, 1H), 7.21 – 7.29 (m, 1H), 7.13 (d, J = 7.83 
Hz, 1H), 7.06 – 7.11 (m, 1H), 6.95 (dt, J = 2.20, 8.44 Hz, 1H), 4.38 (s, 2H), 4.01 (s, 3H) 13C 
NMR (126 MHz, CDCl3) δ 162.70 (d, J = 246.7 Hz), 160.19, 157.59, 150.88, 150.26, 
149.38, 138.83, 138.17 (d, J = 7.6 Hz), 135.52, 130.10 (d, J = 8.5 Hz), 125.06, 124.86, 
124.81 (d, J = 3.1 Hz), 116.19 (d, J = 22.0 Hz), 114.70 (d, J = 21.4 Hz), 102.96, 36.66, 
34.18. HPLC Purity: 98%.
5-Benzyl-6-((3-fluorobenzyl)thio)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (15k)
Method D. White crystalline solid. 57% yield. HRMS (ESI): m/z 381.1180 [M+H]+ 1H 
NMR (500 MHz, CDCl3) δ 8.02 (s, 1H), 7.22 – 7.35 (m, 6H), 7.16 (d, J = 7.83 Hz, 1H), 
7.11 (d, J = 9.78 Hz, 1H), 6.97 (t, J = 8.31 Hz, 1H), 5.36 (br. s., 2H), 4.43 (s, 2H), 3.96 (s, 
3H) 13C NMR (126 MHz, CDCl3) δ 162.69 (d, J = 246.9 Hz), 160.36, 157.77, 150.44, 
138.33 (d, J = 7.5 Hz), 135.33, 135.20, 130.09 (d, J = 8.3 Hz), 128.57, 127.67, 127.28, 
124.70 (d, J = 3.1 Hz), 116.09 (d, J = 22.0 Hz), 114.70 (d, J = 21.0 Hz), 102.58, 46.60, 
36.51, 33.97. HPLC Purity: 99%.
6-((3-Fluorobenzyl)thio)-1-methyl-5-phenethyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (15l)
Method D. White Needles. 72% yield. HRMS (ESI): m/z 395.1341 [M+H]+ 1H NMR (500 
MHz, CDCl3) δ 8.00 (s, 1H), 7.27 – 7.36 (m, 5H), 7.23 (t, J = 7.58 Hz, 2H), 7.17 (d, J = 
9.78 Hz, 1H), 7.00 (dt, J = 2.20, 8.44 Hz, 1H), 4.48 (s, 2H), 4.24 – 4.31 (m, 2H), 3.96 (s, 
3H), 2.97 – 3.04 (m, 2H) 13C NMR (126 MHz, CDCl3) δ 162.76 (d, J = 246.8 Hz), 159.65, 
157.37, 150.47, 138.42 (d, J = 7.6 Hz), 137.64, 135.00, 130.18 (d, J = 8.3 Hz), 128.90, 
128.65, 126.81, 124.76 (d, J = 2.9 Hz), 116.19 (d, J = 22.0 Hz), 114.78 (d, J = 21.2 Hz), 
102.75, 45.68, 36.34, 34.23, 33.98. HPLC Purity: 99%.
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6-((3-Fluorobenzyl)thio)-1,5-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one (15m)
Compound 14 (100mg, 0.47 mmol) was dissolved in 1 mL 8N methylamine in ethanol and 
stirred at RT for 1 h. The volatiles were removed and the residue was dissolved in 1 mL 
DMF to which sodium bicarbonate (80 mg, 0.947 mmol) and 3-fluorobenzyl bromide (70 μl, 
0.57 mmol) were added. The reaction was stirred for 1 h at which point the product was 
precipitated out by the addition of water. The precipitate was collected by filtration, washed 
with water and then hexanes. The precipitate was then taken up in dichloromethane and 
dried with sodium sulfate. The solvent was removed to yield the titled compound as a white 
crystalline solid (122mg, 0.40 mmol, 85 % yield). HRMS (ESI): m/z 305.0864 [M+H]+ 1H 
NMR (500 MHz, CDCl3) δ 7.99 (s, 1H), 7.29 – 7.35 (m, 1H), 7.24 (d, J = 7.83 Hz, 1H), 
7.19 (d, J = 9.78 Hz, 1H), 7.00 (dt, J = 2.45, 8.56 Hz, 1H), 4.49 (s, 2H), 3.96 (s, 3H), 3.55 (s, 
3H) 13C NMR (126 MHz, CDCl3) δ 162.74 (d, J = 246.7 Hz), 160.32, 157.62, 150.46, 
138.42 (d, J = 7.5 Hz), 134.95, 130.17 (d, J = 8.2 Hz), 124.75 (d, J = 2.9 Hz), 116.17 (d, J = 
22.0 Hz), 114.77 (d, J = 21.0 Hz), 102.44, 36.28, 33.95, 29.70. HPLC Purity: 99%.
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ABBREVIATIONS USED
ALDH aldehyde dehydrogenase
ATRA all-trans retinoic acid
CI combination index
CSC cancer stem cell
DEAB diethylamino benzoic acid
EOC epithelial ovarian cancer
EtOAc ethyl acetate
FACS fluorescence-activated cell sorting
FBS fetal bovine serum
Hex Hexanes
NCS isothiocyanate
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MLM mouse liver microsomes
SEM standard error of the mean
SFM serum free medium
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Figure 1. 
Representative ALDH inhibitors 1 – 6 and lead compound 7 (CM39)
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Figure 2. 
(A) Fraction of enzyme activity remaining for 9 ALDH isoforms in the presence of 20 μM 7. 
(B) Percent control ALDHBright cells remaining following treatment of PEO1 cells at the 
specified concentration with DEAB (1) or compound 7 (N=2).
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Figure 3. 
Structure of ALDH1A1 N121S with 7 (2.10 Å, PDB 5TEI). (A) The fluorophenyl of 
compound 7 projects into the lipophilic pocket towards the catalytic cysteine (C303). Key 
residues are labelled. (B) Overlay of Compounds 4 (Cyan, PDB entry 4WP7), 5a (Grey, 
PDB Entry 4X4L), and 7(Orange) bound in ALDH1A1.
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Figure 4. 
Fraction of enzyme activity remaining for 9 ALDH isoforms in the presence of 20μM 15l.
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Figure 5. 
(A) X-Ray crystal structure of 13g bound to ALDH1A1 (PDB code 6DUM). (B) Overlay of 
compounds 7 (PDB code 5TEI) (Orange) and 13g (Green).
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Fig 6. 
ALDH1A2 and 1A3 homology models provide rationale for isoform selectivity of 
Compound 7. (A) Val460 does not clash with o-methyl substituent of N-Phenyl in 
ALDH1A1- Compound 7 structure. (B, C) Docking poses of 7 in ALDH1A2 and 
ALDH1A3, respectively. Red arrow indicates that in both ALDH1A2 and A3, 2-methyl 
substituent at phenyl clashes with Leu477/471.
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Figure 7. 
Compound 11 docks without clashes into the active sites of ALDH1A1, 1A2 and 1A3. (A) 
Structure and ligand interaction plot of Compound 11 docked into ALDH1A1 crystal 
structure. (B,C) Structure and ligand interaction plot of compound 11 docked into 
ALDH1A2, 1A3 homology models respectively.
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Figure 8. 
Docking of compound 12g predicts a similar binding mode to the 13g crystal structure for 
ALDH1A1, 1A2, and 1A3. (A) Structure and ligand interaction plot of Compound 12g 
docked into ALDH1A1 crystal structure. (B,C) Structure and ligand interaction plot of 
compound 12g docked into ALDH1A2, 1A3 homology models respectively.
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Figure 9. 
ALDH1A3 specific residue Glu135 may explain the observed selectivity of compound 15g. 
(A) 15g docked into the ALDH1A3 homology model. (B) Overlay of ALDH1A1 (pink) 
crystal structure with 15g docked in the 1A3 homology model (cyan).
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Figure 10. 
Compounds 15l, 12g, 13g, and 13h inhibit ALDH in cells and deplete cells bearing the 
putative CSC marker CD133. (A, B) Graphs showing changes in ALDEFLUOR activity in 
PEO1 (A) and OVCAR5 (B) cells following the specified treatment (N=3). (C, D) Graphs 
showing changes in the percent of CD133+ cells as determined by flow cytometry following 
48 h drug treatment at the specified concentration (N=3–6) *p≤0.05, **p≤0.01, 
***p≤0.0001.
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Figure 11. 
Compounds 12g, 13g, and 13h synergistically enhance the effect of cisplatin on ovarian 
cancer cell lines and patient derived spheroids. (A, B) Representative heatmaps of 
combination indices for PEO1 (A) and OVCAR5 (B) cells cultured for 72 h in the presence 
of cisplatin and the indicated ALDH inhibitor at the concentrations shown. (N=3) (C) 
Normalized average viability as determined using Alamarblue dye following exposure to the 
specified compounds for 72 hours. (N=5–8) *p≤0.05, ****p≤0.0001 one way ANOVA 
compared to Control. Combination indices for the specified drug combinations calculated 
using CompuSyn software. (CI < 1 indicates synergy) (http://www.combosyn.com).54
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Scheme 1. 
Synthesis of compounds 7, 11, 12a-d,f-h, and 13a-h.a
aReagents and conditions: (a) ArNCS, toluene, reflux; (b) 1N NaOH, reflux; (c) 3-F-
PhCH2Br, K2CO3, DMF, RT; (d) R1-X, K2CO3, DMF, 50°C X = Br, OMs
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Scheme 2. 
Synthesis of analogs 12e, 15a-m.a
aReagents and conditions: (a) NaH, CS2, I2, THF, 0–40°C; (b) R3-NH2, 3-F-PhCH2Br, NaH, 
DMF, 0–20°C; (c) (i) R3-NH2, NaH, DMF, 0–20°C; (ii) 3-F-PhCH2Br, K2CO3, DMF, RT; 
(d) (i) MeNH2, EtOH; (ii) 3-F-PhCH2Br, K2CO3, DMF, RT
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Table 1.
Characterization of N-1 alkylated analogs
Cmpd No. R1 R2 ALDH IC50
a
 (μM) or % control at 20 μMb cLogP Aq. Sol.c(μM) MLM t1/2(min)
1A1 1A2 1A3 2 (min)
7 H Me 0.9 ± 0.2 53% 53% 85% 5.2 2 9
11 H H 0.45 ± 0.03 0.67 ± 0.08 0.39 ± 0.02 94% 4.7
12a Me Me 0.66 ± 0.06 52% 4 ± 1 94% 4.8 38
12b c-PrCH2 Me 0.18 ± 0.01 >10 >10 100% 5.6
12c 3-oxetanyl Me 0.26± 0.03 6 ± 1 60% 96% 4.7
12d 3-oxetanyl-CH2 Me 0.42 ± 0.01 45% 58% 97% 4.7
12e Me H 0.08 ± 0.01 0.15 ± 0.01 0.09 ± 0.01 100% 4.3
<0.7 (BLQ)d 8
12f c-PrCH2 H 0.56 ± 0.03 1.26 ± 0.08 0.55 ± 0.02 83% 5.1
12g 3-oxetanyl H 0.13 ± 0.01 0.23 ± 0.01 0.17 ± 0.01 94% 4.1 8
12h 3-oxetanyl-CH2 H 0.34 ± 0.07 1.1 ± 0.1 0.61 ± 0.09 96% 4.1
Values are expressed as
a
 Mean ± SEM (n=3)
b
 Mean (n=3)
c
 Thermodynamic solubility analysis was performed by Analiza Inc. using quantitative nitrogen detection.(www.analiza.com)
d
BLQ = below limit of quantitation.
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Table 2.
Characterization of N-2 alkylated analogs
Cmpd No. R1 R2 ALDH IC50
a(μM) or % control at 20 μMb cLogP Aq. Sol.c(μM) MLM t1/2
1A1 1A2 1A3 2 (min)
13a Me Me 0.67 ± 0.07 6 ± 1 2.2 ± 0.4 100% 5.3
13b c-Pr-CH2 Me 0.10 ± 0.01 >10 1.0 ± 0.1 100% 6.1
13c 3-oxetanyl Me 0.44 ± 0.06 8 ± 1 3.9 ± 0.4 100% 5.2
13d 3-oxetanyl-CH2 Me 0.20 ± 0.03 3.9 ± 0.3 2.6 ± 0.3 98% 5.2
13e Me H 0.25 ± 0.01 0.34 ± 0.05 0.13 ± 0.01 94% 4.8 69 13
13f c-Pr-CH2 H 0.13 ± 0.03 1.1 ± 0.2 0.17 ± 0.03 87% 5.6
13g 3-oxetanyl H 0.08 ± 0.01 0.25 ± 0.04 0.12 ± 0.02 97% 4.7 5 23
13h 3-oxetanyl-CH2 H 0.27 ± 0.01 0.48 ± 0.04 0.13 ± 0.01 99% 4.7 53 27
Values are expressed as
a
 Mean ± SEM (n=3)
b
 Mean (n=3)
c
 Thermodynamic solubility analysis was performed by Analiza Inc. using quantitative nitrogen detection.(www.analiza.com)
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Table 3.
Characterization of N-phenyl modifications
Cmpd No. R3 IC50
a
 (μM) or % control at 20 μMb Aq. Sol.d (μM)
ALDH
1A1 1A2 1A3 2
12a 2-Me-Ph 0.66 ± 0.06 52% 4 ± 1 94% 38
12e Ph 0.08 ± 0.01 0.15 ± 0.01 0.09 ± 0.01 100%
<0.7 (BLQ)e
15a 2-Cl-Ph 0.25 ±0.04 75% 10 ± 2 100%
15b 3-Cl-Ph 4.1 ± 0.6 0.56 ± 0.06 2.6 ± 0.3 100% 55
15c 4-Cl-Ph 69% 1.1 ± 0.1 0.75 ± 0.05 100%
15d 2-F-Ph 0.11 ± 0.01 8%c 1%c 90%
15e 2-OMe-Ph 0.97 ± 0.10 >10 >10 100%
15f 3-OMe-Ph 41% 1.3 ± 0.1 44% 82%
15g 4-OMe-Ph 8.2 ± 0.7 1.77 ± 0.09 0.78 ± 0.09 86%
15h 3-Pyridyl 3.83 ± 0.03 45% 117% 99%
15i 4-Pyridyl 52% 52% 60% 97%
15j 2-Pyridyl 2.4 ± 0.4 64% 67% 99%
15k Bn 0.89 ± 0.13 0.72 ± 0.04 >10 100% 5
15l Ph-CH2CH2 1.4 ± 0.15 0.9 ± 0.1 0.18 ± 0.04 87% 3
15m Me 4.1 ± 0.37 79% 66% 95%
Values are expressed as
a
 Mean ± SEM (n=3)
b
 Mean (n=3)
c
 Dose response curves were not satisfactory for IC50 determination
d
Thermodynamic solubility analysis was performed by Analiza Inc. using quantitative nitrogen detection. (www.analiza.com)
e
BLQ = below limit of quantitation.
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Table 6.
In Vivo exposure following IP injection in mice.
Compound Plasma Concentration (μM) AUC0–7hobs
0.5 h 2 h 4 h 7 h (hr·μM)
13g 7.6 ± 0.8 5.2 ± 1.0 3.0 ± 1.3 0.9 ± 0.7 27.8
13h 5.6 ± 0.2 2.6 ± 0.6 0.6 ± 0.2 0.1 ± 0.1 11
Compounds at the specified doses were administered by a single intraperitoneal injection of 10mg/kg to CD-1 mice. Values expressed as Mean ± 
S.D for 3 mice at each timepoint.
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